[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fo8n84JxKfB_GEJMdjXz-6VTyJeXa38zoa9W_j2aQV9U":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University of Illinois at Chicago",[4],502,false,162,15,360108,58,387,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Obesity",28,{"name":18,"count":19},"Depression",22,{"name":21,"count":22},"Multiple Sclerosis",13,{"name":24,"count":25},"Sickle Cell Disease",11,{"name":27,"count":25},"Stroke",{"name":29,"count":25},"Breast Cancer",{"name":31,"count":32},"Prostate Cancer",10,{"name":34,"count":32},"Anxiety",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04442191","Convalescent Plasma as a Possible Treatment for COVID-19","2021-05-05","Convalescent plasma",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04704141","Relationship of the Microenvironment and Male Fertility","2025-06","Hormone replacement therapy",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04048278","Lidocaine Infusion in Pancreatic Cancer","2025-11-08","Lidocaine Hydrochloride",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04547439","Sleep, Diabetic Retinopathy and Melatonin","2026-02-02","Melatonin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06591091","Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","2026-03","Clemastine Fumarate",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06919081","Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease","2026-03-15","Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06296836","Effect of Continuing Versus Holding Metformin During Hospitalizations.","2026-03-31","Metformin",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT03121014","Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine\u002FBusulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","2026-04","Fludarabine",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04891068","BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer","2026-05","Azacitidine",{"nctId":82,"briefTitle":83,"date":79,"intervention":84},"NCT03121001","Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","ATG",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,121,139,163,184,211,229,247,274,363,396,455,498,524,553,589,632,654,676,700,725,743,761,779,797,820,838,858,878,901,929,947,965,991,1009,1027,1045,1068,1095,1113,1139,1165,1183,1201,1219,1243,1261,1285,1303,1321,1339,1376,1398,1416,1444,1471,1489,1507,1528,1569,1605,1630,1648,1666,1691,1709,1734,1760,1778,1796,1814,1832,1850,1868,1886,1904,1922,1940,1958,1983,2009,2034,2059,2085,2111,2129,2147,2176,2201,2226,2251,2276,2302,2328,2354,2380,2398,2435,2464,2499,2524,2549,2574,2592,2610,2632,2656,2680,2705,2723,2741,2759,2777,2806,2824,2850,2868,2886,2904,2928,2946,2970,2988,3013,3031,3055,3079,3104,3130,3153,3179,3204,3222,3240,3274,3292,3310,3339,3357,3375,3393,3418,3440,3458,3489,3507,3534,3560,3578,3602,3626,3651,3674,3701,3719,3754,3777,3795,3822,3840,3865,3889,3907,3925,3953,3978,4001,4026,4050,4073,4097,4119,4141,4168],{"intervention":94,"totalTrials":95,"cells":96},"Flecainide",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":119},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":8,"conditions":115,"interventions":117},"NCT02347111","Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation","RECRUITING",[90],"2026-06-30","2020-12-31",[116],"Atrial Fibrillation",[94,118],"Sotalol",{"trials":120,"activeCount":99},[],{"intervention":118,"totalTrials":95,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":137},{"trials":124,"activeCount":99},[],{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":99},[],{"trials":132,"activeCount":95,"soonestReadout":113},[133],{"nctId":109,"briefTitle":110,"status":111,"phases":134,"primaryCompletion":113,"completion":113,"start":114,"enrollment":8,"conditions":135,"interventions":136},[90],[116],[94,118],{"trials":138,"activeCount":99},[],{"intervention":140,"totalTrials":95,"cells":141},"Abemaciclib",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":161},{"trials":143,"activeCount":99},[],{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":99},[],{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":95,"soonestReadout":156},[152],{"nctId":153,"briefTitle":154,"status":111,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"NCT06169371","Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)",[90],"2030-11","2023-12-28",50,[29],[140,140,140],{"trials":162,"activeCount":99},[],{"intervention":70,"totalTrials":95,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":182},{"trials":166,"activeCount":99},[],{"trials":168,"activeCount":99},[],{"trials":170,"activeCount":99},[],{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":95,"soonestReadout":69},[175],{"nctId":67,"briefTitle":68,"status":111,"phases":176,"primaryCompletion":69,"completion":113,"start":177,"enrollment":178,"conditions":179,"interventions":181},[90],"2025-01-21",300,[180],"Diabetes Mellitus, Type 2",[70],{"trials":183,"activeCount":99},[],{"intervention":185,"totalTrials":95,"cells":186},"Granisetron Transdermal Patch",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":209},{"trials":188,"activeCount":99},[],{"trials":190,"activeCount":99},[],{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":99},[],{"trials":196,"activeCount":95,"soonestReadout":201},[197],{"nctId":198,"briefTitle":199,"status":111,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT04150614","BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron",[90],"2026-07","2020-05-14",90,[205],"Nausea With Vomiting Chemotherapy-Induced",[185,207,208],"Intravenous Dexamethasone","Ondansetron",{"trials":210,"activeCount":99},[],{"intervention":207,"totalTrials":95,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":227},{"trials":214,"activeCount":99},[],{"trials":216,"activeCount":99},[],{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":95,"soonestReadout":201},[223],{"nctId":198,"briefTitle":199,"status":111,"phases":224,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":225,"interventions":226},[90],[205],[185,207,208],{"trials":228,"activeCount":99},[],{"intervention":208,"totalTrials":95,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":245},{"trials":232,"activeCount":99},[],{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":99},[],{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":95,"soonestReadout":201},[241],{"nctId":198,"briefTitle":199,"status":111,"phases":242,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":243,"interventions":244},[90],[205],[185,207,208],{"trials":246,"activeCount":99},[],{"intervention":248,"totalTrials":95,"cells":249},"Deferoxamine",{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":270,"NA":272},{"trials":251,"activeCount":99},[],{"trials":253,"activeCount":99},[],{"trials":255,"activeCount":99},[],{"trials":257,"activeCount":95,"soonestReadout":263},[258],{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":269},"NCT07162363","Synergistic Minimally Invasive Surgery and Deferoxamine in ICH","NOT_YET_RECRUITING",[88,89],"2028-12-30","2026-03-01",240,[267,268],"Intracerebral Hemorrhage","ICH - Intracerebral Hemorrhage",[248],{"trials":271,"activeCount":99},[],{"trials":273,"activeCount":99},[],{"intervention":275,"totalTrials":276,"cells":277},"Cyclophosphamide",6,{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":296,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[282],{"nctId":283,"briefTitle":284,"status":285,"phases":286,"start":287,"enrollment":288,"conditions":289,"interventions":290},"NCT00002616","Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer","UNKNOWN",[87],"1995-02",36,[29],[291,292,293,294,295],"aldesleukin","filgrastim","carboplatin","cyclophosphamide","thiotepa",{"trials":297,"activeCount":356,"soonestReadout":79},[298,311,326,337,345],{"nctId":299,"briefTitle":300,"status":301,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":22,"conditions":305,"interventions":307},"NCT04083963","Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer","ACTIVE_NOT_RECRUITING",[88],"2026-09-27","2019-08-09",[306],"Triple Negative Breast Cancer",[308,309,310,275],"Carboplatin","Paclitaxel","Doxorubicin",{"nctId":312,"briefTitle":313,"status":111,"phases":314,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":324},"NCT06802315","Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)",[88],"2030-03","2032-03","2025-02-04",38,[320,321,322,323],"Acute Myeloid Leukemia, Relapsed, Adult","Acute Myeloid Leukemia Refractory","Chronic Myeloid Leukemia - Accelerated Phase","Myelodysplastic Syndromes",[275,75,325],"Busulfan",{"nctId":327,"briefTitle":328,"status":329,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT01749293","Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation","TERMINATED",[88],"2014-05-15","2012-08-30",3,[335],"Hematologic Malignancies",[75,325,275],{"nctId":82,"briefTitle":83,"status":111,"phases":338,"primaryCompletion":79,"completion":79,"start":339,"enrollment":158,"conditions":340,"interventions":341},[88],"2017-03-20",[24],[84,342,294,343,344],"fludarabine","Sirolimus","mycophenolate mofetil",{"nctId":346,"briefTitle":347,"status":111,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":353},"NCT06085742","BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer",[88],"2034-09","2023-11-22",25,[29],[275,354,355],"Methotrexate","Capecitabine",4,{"trials":358,"activeCount":99},[],{"trials":360,"activeCount":99},[],{"trials":362,"activeCount":99},[],{"intervention":75,"totalTrials":356,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":366,"activeCount":99},[],{"trials":368,"activeCount":99},[],{"trials":370,"activeCount":333,"soonestReadout":74},[371,378,382,386],{"nctId":72,"briefTitle":73,"status":301,"phases":372,"primaryCompletion":74,"completion":74,"start":373,"enrollment":318,"conditions":374,"interventions":376},[88],"2017-04-24",[375,323],"Acute Myeloid Leukemia",[75,325,84,377,354],"Tacrolimus",{"nctId":312,"briefTitle":313,"status":111,"phases":379,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":380,"interventions":381},[88],[320,321,322,323],[275,75,325],{"nctId":327,"briefTitle":328,"status":329,"phases":383,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":384,"interventions":385},[88],[335],[75,325,275],{"nctId":82,"briefTitle":83,"status":111,"phases":387,"primaryCompletion":79,"completion":79,"start":339,"enrollment":158,"conditions":388,"interventions":389},[88],[24],[84,342,294,343,344],{"trials":391,"activeCount":99},[],{"trials":393,"activeCount":99},[],{"trials":395,"activeCount":99},[],{"intervention":309,"totalTrials":356,"cells":397},{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":399,"activeCount":99},[],{"trials":401,"activeCount":99},[],{"trials":403,"activeCount":435,"soonestReadout":303},[404,418,422],{"nctId":405,"briefTitle":406,"status":285,"phases":407,"start":408,"enrollment":409,"conditions":410,"interventions":414},"NCT00003251","Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer",[87,88],"1997-12",46,[411,412,413],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Head and Neck Cancer","Radiation Toxicity",[415,416,417],"amifostine trihydrate","cisplatin","paclitaxel",{"nctId":299,"briefTitle":300,"status":301,"phases":419,"primaryCompletion":303,"completion":303,"start":304,"enrollment":22,"conditions":420,"interventions":421},[88],[306],[308,309,310,275],{"nctId":423,"briefTitle":424,"status":111,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"enrollment":16,"conditions":428,"interventions":430},"NCT06441890","BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer",[88],"2028-06","2024-12-05",[29,429],"HER2-positive Breast Cancer",[309,431,432,433,434],"Nab-paclitaxel","Docetaxel","Trastuzumab","Pertuzumab",2,{"trials":437,"activeCount":99},[],{"trials":439,"activeCount":99},[],{"trials":441,"activeCount":95,"soonestReadout":446},[442],{"nctId":443,"briefTitle":444,"status":111,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":451},"NCT06576635","LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients",[91],"2026-09","2024-12-16",29,[450],"NSCLC",[432,309,452,453,454],"Gemcitabine","Pemetrexed","Vinorelbine",{"intervention":354,"totalTrials":333,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":471,"PHASE4":473,"NA":496},{"trials":458,"activeCount":99},[],{"trials":460,"activeCount":99},[],{"trials":462,"activeCount":435,"soonestReadout":74},[463,467],{"nctId":72,"briefTitle":73,"status":301,"phases":464,"primaryCompletion":74,"completion":74,"start":373,"enrollment":318,"conditions":465,"interventions":466},[88],[375,323],[75,325,84,377,354],{"nctId":346,"briefTitle":347,"status":111,"phases":468,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":469,"interventions":470},[88],[29],[275,354,355],{"trials":472,"activeCount":99},[],{"trials":474,"activeCount":99},[475],{"nctId":476,"briefTitle":477,"status":478,"phases":479,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":486},"NCT02451748","IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","COMPLETED",[90],"2017-09","2017-12","2015-08",32,[485],"Rheumatoid Arthritis",[487,487,488,489,490,491,492,493,494,354,495],"Certolizumab pegol","Hydroxychloroquine","Sulfasalazine","Medrol","Prednisone","Triamcinolone","Naproxen","Leflunomide","humira",{"trials":497,"activeCount":99},[],{"intervention":325,"totalTrials":333,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":501,"activeCount":99},[],{"trials":503,"activeCount":99},[],{"trials":505,"activeCount":435,"soonestReadout":74},[506,510,514],{"nctId":72,"briefTitle":73,"status":301,"phases":507,"primaryCompletion":74,"completion":74,"start":373,"enrollment":318,"conditions":508,"interventions":509},[88],[375,323],[75,325,84,377,354],{"nctId":312,"briefTitle":313,"status":111,"phases":511,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":512,"interventions":513},[88],[320,321,322,323],[275,75,325],{"nctId":327,"briefTitle":328,"status":329,"phases":515,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":516,"interventions":517},[88],[335],[75,325,275],{"trials":519,"activeCount":99},[],{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":99},[],{"intervention":343,"totalTrials":435,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":99},[],{"trials":531,"activeCount":435,"soonestReadout":79},[532,543],{"nctId":533,"briefTitle":534,"status":301,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":541},"NCT01499888","Ph I\u002FII Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)",[87,88],"2028-09-23","2029-10","2011-11-11",45,[24],[542,343],"Alemtuzumab",{"nctId":82,"briefTitle":83,"status":111,"phases":544,"primaryCompletion":79,"completion":79,"start":339,"enrollment":158,"conditions":545,"interventions":546},[88],[24],[84,342,294,343,344],{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":99},[],{"trials":552,"activeCount":99},[],{"intervention":554,"totalTrials":435,"cells":555},"Pembrolizumab",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":569,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":95,"soonestReadout":201},[560],{"nctId":561,"briefTitle":562,"status":111,"phases":563,"primaryCompletion":201,"completion":201,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT04427293","Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)",[87],"2020-07-09",12,[306],[568,554],"Lenvatinib",{"trials":570,"activeCount":95,"soonestReadout":575},[571],{"nctId":572,"briefTitle":573,"status":111,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":288,"conditions":577,"interventions":579},"NCT05613413","A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)",[88],"2028-09","2022-12-28",[578],"Metastatic Squamous Non-Small Cell Lung Carcinoma",[580,581,554,582],"Pacliltaxel or Nab-paclitaxel","Carboplatin or Cisplatin","Cabozantinib",{"trials":584,"activeCount":99},[],{"trials":586,"activeCount":99},[],{"trials":588,"activeCount":99},[],{"intervention":84,"totalTrials":333,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":592,"activeCount":99},[],{"trials":594,"activeCount":99},[],{"trials":596,"activeCount":435,"soonestReadout":74},[597,601],{"nctId":72,"briefTitle":73,"status":301,"phases":598,"primaryCompletion":74,"completion":74,"start":373,"enrollment":318,"conditions":599,"interventions":600},[88],[375,323],[75,325,84,377,354],{"nctId":82,"briefTitle":83,"status":111,"phases":602,"primaryCompletion":79,"completion":79,"start":339,"enrollment":158,"conditions":603,"interventions":604},[88],[24],[84,342,294,343,344],{"trials":606,"activeCount":99},[],{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[611],{"nctId":612,"briefTitle":613,"status":478,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":629},"NCT01499147","Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies",[91],"2013-05","2000-02",100,[375,619,620,621,622,623,624,625,626,627,628],"Acute Leukemia","Chronic Myelogenous Leukemia","Malignant Lymphoma","Hodgkin's Disease","Multiple Myeloma","Lymphocytic Leukemia","Myeloproliferative Disorder","Polycythemia Vera","Myelofibrosis","Aplastic Anemia",[630,631,84],"fludarabine\u002Fbusulfan","fludarabine\u002F melphalan",{"intervention":432,"totalTrials":435,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":635,"activeCount":99},[],{"trials":637,"activeCount":99},[],{"trials":639,"activeCount":95,"soonestReadout":426},[640],{"nctId":423,"briefTitle":424,"status":111,"phases":641,"primaryCompletion":426,"completion":426,"start":427,"enrollment":16,"conditions":642,"interventions":643},[88],[29,429],[309,431,432,433,434],{"trials":645,"activeCount":99},[],{"trials":647,"activeCount":99},[],{"trials":649,"activeCount":95,"soonestReadout":446},[650],{"nctId":443,"briefTitle":444,"status":111,"phases":651,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":652,"interventions":653},[91],[450],[432,309,452,453,454],{"intervention":308,"totalTrials":435,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":664,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":99},[660],{"nctId":283,"briefTitle":284,"status":285,"phases":661,"start":287,"enrollment":288,"conditions":662,"interventions":663},[87],[29],[291,292,293,294,295],{"trials":665,"activeCount":95,"soonestReadout":303},[666],{"nctId":299,"briefTitle":300,"status":301,"phases":667,"primaryCompletion":303,"completion":303,"start":304,"enrollment":22,"conditions":668,"interventions":669},[88],[306],[308,309,310,275],{"trials":671,"activeCount":99},[],{"trials":673,"activeCount":99},[],{"trials":675,"activeCount":99},[],{"intervention":677,"totalTrials":95,"cells":678},"Mesenchymal Stromal Cells",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":95,"soonestReadout":689},[685],{"nctId":686,"briefTitle":687,"status":111,"phases":688,"primaryCompletion":689,"completion":689,"start":690,"enrollment":318,"conditions":691,"interventions":693},"NCT05705024","Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells",[88],"2026-09-28","2023-09-29",[692],"Corneal Ulcer",[677],{"trials":695,"activeCount":99},[],{"trials":697,"activeCount":99},[],{"trials":699,"activeCount":99},[],{"intervention":701,"totalTrials":95,"cells":702},"Conditioning regimen with half-matched (haploidentical) stem cell transplant",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":719,"PHASE4":721,"NA":723},{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":95,"soonestReadout":713},[709],{"nctId":710,"briefTitle":711,"status":111,"phases":712,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":718},"NCT04187105","BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)",[88],"2026-12","2020-01-27",27,[619,717],"MDS",[701,701,701,701,701,701,701],{"trials":720,"activeCount":99},[],{"trials":722,"activeCount":99},[],{"trials":724,"activeCount":99},[],{"intervention":310,"totalTrials":95,"cells":726},{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":737,"PHASE4":739,"NA":741},{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":99},[],{"trials":732,"activeCount":95,"soonestReadout":303},[733],{"nctId":299,"briefTitle":300,"status":301,"phases":734,"primaryCompletion":303,"completion":303,"start":304,"enrollment":22,"conditions":735,"interventions":736},[88],[306],[308,309,310,275],{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"trials":742,"activeCount":99},[],{"intervention":431,"totalTrials":95,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":95,"soonestReadout":426},[751],{"nctId":423,"briefTitle":424,"status":111,"phases":752,"primaryCompletion":426,"completion":426,"start":427,"enrollment":16,"conditions":753,"interventions":754},[88],[29,429],[309,431,432,433,434],{"trials":756,"activeCount":99},[],{"trials":758,"activeCount":99},[],{"trials":760,"activeCount":99},[],{"intervention":433,"totalTrials":95,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":764,"activeCount":99},[],{"trials":766,"activeCount":99},[],{"trials":768,"activeCount":95,"soonestReadout":426},[769],{"nctId":423,"briefTitle":424,"status":111,"phases":770,"primaryCompletion":426,"completion":426,"start":427,"enrollment":16,"conditions":771,"interventions":772},[88],[29,429],[309,431,432,433,434],{"trials":774,"activeCount":99},[],{"trials":776,"activeCount":99},[],{"trials":778,"activeCount":99},[],{"intervention":434,"totalTrials":95,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":782,"activeCount":99},[],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":95,"soonestReadout":426},[787],{"nctId":423,"briefTitle":424,"status":111,"phases":788,"primaryCompletion":426,"completion":426,"start":427,"enrollment":16,"conditions":789,"interventions":790},[88],[29,429],[309,431,432,433,434],{"trials":792,"activeCount":99},[],{"trials":794,"activeCount":99},[],{"trials":796,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":800,"activeCount":99},[],{"trials":802,"activeCount":99},[],{"trials":804,"activeCount":95,"soonestReadout":54},[805],{"nctId":52,"briefTitle":53,"status":111,"phases":806,"primaryCompletion":54,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":813},[88],"2026-06","2021-02-03",42,[811,812],"Diabetes Mellitus","Diabetic Retinopathy",[55],{"trials":815,"activeCount":99},[],{"trials":817,"activeCount":99},[],{"trials":819,"activeCount":99},[],{"intervention":377,"totalTrials":95,"cells":821},{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":823,"activeCount":99},[],{"trials":825,"activeCount":99},[],{"trials":827,"activeCount":95,"soonestReadout":74},[828],{"nctId":72,"briefTitle":73,"status":301,"phases":829,"primaryCompletion":74,"completion":74,"start":373,"enrollment":318,"conditions":830,"interventions":831},[88],[375,323],[75,325,84,377,354],{"trials":833,"activeCount":99},[],{"trials":835,"activeCount":99},[],{"trials":837,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":95,"soonestReadout":39},[846],{"nctId":37,"briefTitle":38,"status":111,"phases":847,"primaryCompletion":39,"completion":39,"start":848,"enrollment":158,"conditions":849,"interventions":851},[88],"2020-05-05",[850],"COVID-19",[40],{"trials":853,"activeCount":99},[],{"trials":855,"activeCount":99},[],{"trials":857,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":861,"activeCount":99},[],{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":95,"soonestReadout":59},[866],{"nctId":57,"briefTitle":58,"status":261,"phases":867,"primaryCompletion":59,"completion":59,"start":868,"enrollment":869,"conditions":870,"interventions":871},[88],"2025-09",80,[18],[60],{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":881,"activeCount":99},[],{"trials":883,"activeCount":99},[],{"trials":885,"activeCount":95,"soonestReadout":79},[886],{"nctId":77,"briefTitle":78,"status":111,"phases":887,"primaryCompletion":79,"completion":79,"start":888,"enrollment":889,"conditions":890,"interventions":894},[88],"2022-01-10",40,[891,892,893],"Breast Cancer Invasive","Early-stage Breast Cancer","High Risk Breast Carcinoma",[80],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[],{"trials":900,"activeCount":99},[],{"intervention":902,"totalTrials":95,"cells":903},"FIM intervention arm",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":905,"activeCount":99},[],{"trials":907,"activeCount":99},[],{"trials":909,"activeCount":95,"soonestReadout":914},[910],{"nctId":911,"briefTitle":912,"status":261,"phases":913,"primaryCompletion":914,"completion":915,"start":264,"enrollment":916,"conditions":917,"interventions":921},"NCT07332741","FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control",[88],"2029-03","2029-06",150,[918,919,920],"Hypertension","Hypertension (HTN)","Obesity & Overweight",[902,922],"FIM Usual Care Arm",{"trials":924,"activeCount":99},[],{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[],{"intervention":922,"totalTrials":95,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":95,"soonestReadout":914},[937],{"nctId":911,"briefTitle":912,"status":261,"phases":938,"primaryCompletion":914,"completion":915,"start":264,"enrollment":916,"conditions":939,"interventions":940},[88],[918,919,920],[902,922],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[],{"intervention":542,"totalTrials":95,"cells":948},{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":950,"activeCount":99},[],{"trials":952,"activeCount":99},[],{"trials":954,"activeCount":95,"soonestReadout":536},[955],{"nctId":533,"briefTitle":534,"status":301,"phases":956,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":957,"interventions":958},[87,88],[24],[542,343],{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"intervention":966,"totalTrials":95,"cells":967},"Lactobacillus sakei proBio65",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":969,"activeCount":99},[],{"trials":971,"activeCount":99},[],{"trials":973,"activeCount":95,"soonestReadout":978},[974],{"nctId":975,"briefTitle":976,"status":111,"phases":977,"primaryCompletion":978,"completion":979,"start":980,"enrollment":981,"conditions":982,"interventions":984},"NCT05427695","Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis",[88],"2028-03-31","2028-07-30","2025-02-05",60,[983],"Chronic Rhinosinusitis (Diagnosis)",[966],{"trials":986,"activeCount":99},[],{"trials":988,"activeCount":99},[],{"trials":990,"activeCount":99},[],{"intervention":580,"totalTrials":95,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":95,"soonestReadout":575},[999],{"nctId":572,"briefTitle":573,"status":111,"phases":1000,"primaryCompletion":575,"completion":575,"start":576,"enrollment":288,"conditions":1001,"interventions":1002},[88],[578],[580,581,554,582],{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":99},[],{"trials":1008,"activeCount":99},[],{"intervention":581,"totalTrials":95,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1012,"activeCount":99},[],{"trials":1014,"activeCount":99},[],{"trials":1016,"activeCount":95,"soonestReadout":575},[1017],{"nctId":572,"briefTitle":573,"status":111,"phases":1018,"primaryCompletion":575,"completion":575,"start":576,"enrollment":288,"conditions":1019,"interventions":1020},[88],[578],[580,581,554,582],{"trials":1022,"activeCount":99},[],{"trials":1024,"activeCount":99},[],{"trials":1026,"activeCount":99},[],{"intervention":582,"totalTrials":95,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1039,"PHASE4":1041,"NA":1043},{"trials":1030,"activeCount":99},[],{"trials":1032,"activeCount":99},[],{"trials":1034,"activeCount":95,"soonestReadout":575},[1035],{"nctId":572,"briefTitle":573,"status":111,"phases":1036,"primaryCompletion":575,"completion":575,"start":576,"enrollment":288,"conditions":1037,"interventions":1038},[88],[578],[580,581,554,582],{"trials":1040,"activeCount":99},[],{"trials":1042,"activeCount":99},[],{"trials":1044,"activeCount":99},[],{"intervention":65,"totalTrials":95,"cells":1046},{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1048,"activeCount":99},[],{"trials":1050,"activeCount":99},[],{"trials":1052,"activeCount":95,"soonestReadout":64},[1053],{"nctId":62,"briefTitle":63,"status":111,"phases":1054,"primaryCompletion":64,"completion":1055,"start":1056,"enrollment":1057,"conditions":1058,"interventions":1061},[88],"2026-06-15","2025-08-01",24,[1059,1060],"Persistent Corneal Epithelial Defect","Corneal Epithelial Disorders",[65],{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"intervention":1069,"totalTrials":95,"cells":1070},"Neoadjuvant chemotherapy",{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[],{"trials":1076,"activeCount":95,"soonestReadout":1081},[1077],{"nctId":1078,"briefTitle":1079,"status":261,"phases":1080,"primaryCompletion":1081,"completion":1082,"start":79,"enrollment":1083,"conditions":1084,"interventions":1087},"NCT07581405","GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer",[88],"2028-05","2030-05",26,[1085,1086],"Gastric Adenocarcinoma","Gastric Cancer",[1069,1088],"Olanzapine",{"trials":1090,"activeCount":99},[],{"trials":1092,"activeCount":99},[],{"trials":1094,"activeCount":99},[],{"intervention":1088,"totalTrials":95,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":99},[],{"trials":1102,"activeCount":95,"soonestReadout":1081},[1103],{"nctId":1078,"briefTitle":1079,"status":261,"phases":1104,"primaryCompletion":1081,"completion":1082,"start":79,"enrollment":1083,"conditions":1105,"interventions":1106},[88],[1085,1086],[1069,1088],{"trials":1108,"activeCount":99},[],{"trials":1110,"activeCount":99},[],{"trials":1112,"activeCount":99},[],{"intervention":1114,"totalTrials":95,"cells":1115},"Empagliflozin",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1117,"activeCount":99},[],{"trials":1119,"activeCount":99},[],{"trials":1121,"activeCount":95,"soonestReadout":537},[1122],{"nctId":1123,"briefTitle":1124,"status":111,"phases":1125,"primaryCompletion":537,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1132},"NCT07175051","Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin",[88],"2030-10","2026-04-08",20,[1130,1131],"Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)","Albuminuria",[1114],{"trials":1134,"activeCount":99},[],{"trials":1136,"activeCount":99},[],{"trials":1138,"activeCount":99},[],{"intervention":1140,"totalTrials":95,"cells":1141},"Aromatase Inhibitors",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1143,"activeCount":99},[],{"trials":1145,"activeCount":99},[],{"trials":1147,"activeCount":95,"soonestReadout":1081},[1148],{"nctId":1149,"briefTitle":1150,"status":261,"phases":1151,"primaryCompletion":1081,"completion":1152,"start":79,"enrollment":617,"conditions":1153,"interventions":1156},"NCT07596212","BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder",[87,88],"2031-05",[892,1154,1155,29],"Hypoactive Sexual Desire Disorder","Hormone Receptor Positive Breast Carcinoma",[1140,1157,1158],"Bupropion","GnRH agonist",{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"intervention":1157,"totalTrials":95,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1168,"activeCount":99},[],{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":95,"soonestReadout":1081},[1173],{"nctId":1149,"briefTitle":1150,"status":261,"phases":1174,"primaryCompletion":1081,"completion":1152,"start":79,"enrollment":617,"conditions":1175,"interventions":1176},[87,88],[892,1154,1155,29],[1140,1157,1158],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"trials":1182,"activeCount":99},[],{"intervention":1158,"totalTrials":95,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":95,"soonestReadout":1081},[1191],{"nctId":1149,"briefTitle":1150,"status":261,"phases":1192,"primaryCompletion":1081,"completion":1152,"start":79,"enrollment":617,"conditions":1193,"interventions":1194},[87,88],[892,1154,1155,29],[1140,1157,1158],{"trials":1196,"activeCount":99},[],{"trials":1198,"activeCount":99},[],{"trials":1200,"activeCount":99},[],{"intervention":344,"totalTrials":95,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1204,"activeCount":99},[],{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":95,"soonestReadout":79},[1209],{"nctId":82,"briefTitle":83,"status":111,"phases":1210,"primaryCompletion":79,"completion":79,"start":339,"enrollment":158,"conditions":1211,"interventions":1212},[88],[24],[84,342,294,343,344],{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[],{"trials":1218,"activeCount":99},[],{"intervention":1220,"totalTrials":95,"cells":1221},"Glycyrrhizin - 75 mg",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1223,"activeCount":99},[],{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":95,"soonestReadout":1232},[1228],{"nctId":1229,"briefTitle":1230,"status":111,"phases":1231,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":981,"conditions":1234,"interventions":1235},"NCT06378346","GU-01: Glycyrrhizin in Prostate Cancer",[88],"2027-03","2024-07-25",[31],[1220,1236],"Glycyrrhizin - 150 mg",{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[],{"trials":1242,"activeCount":99},[],{"intervention":1236,"totalTrials":95,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1255,"PHASE4":1257,"NA":1259},{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":95,"soonestReadout":1232},[1251],{"nctId":1229,"briefTitle":1230,"status":111,"phases":1252,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":981,"conditions":1253,"interventions":1254},[88],[31],[1220,1236],{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":99},[],{"trials":1260,"activeCount":99},[],{"intervention":1262,"totalTrials":95,"cells":1263},"Isatuximab",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1265,"activeCount":99},[],{"trials":1267,"activeCount":99},[],{"trials":1269,"activeCount":95,"soonestReadout":1274},[1270],{"nctId":1271,"briefTitle":1272,"status":111,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":158,"conditions":1276,"interventions":1277},"NCT05344833","Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma",[88],"2030-12","2023-01-05",[623],[1262,1278],"Lenalidomide",{"trials":1280,"activeCount":99},[],{"trials":1282,"activeCount":99},[],{"trials":1284,"activeCount":99},[],{"intervention":1278,"totalTrials":95,"cells":1286},{"EARLY_PHASE1":1287,"PHASE1":1289,"PHASE2":1291,"PHASE3":1297,"PHASE4":1299,"NA":1301},{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":99},[],{"trials":1292,"activeCount":95,"soonestReadout":1274},[1293],{"nctId":1271,"briefTitle":1272,"status":111,"phases":1294,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":158,"conditions":1295,"interventions":1296},[88],[623],[1262,1278],{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":99},[],{"trials":1302,"activeCount":99},[],{"intervention":355,"totalTrials":95,"cells":1304},{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1306,"activeCount":99},[],{"trials":1308,"activeCount":99},[],{"trials":1310,"activeCount":95,"soonestReadout":349},[1311],{"nctId":346,"briefTitle":347,"status":111,"phases":1312,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":1313,"interventions":1314},[88],[29],[275,354,355],{"trials":1316,"activeCount":99},[],{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":99},[],{"intervention":568,"totalTrials":95,"cells":1322},{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1331,"PHASE3":1333,"PHASE4":1335,"NA":1337},{"trials":1324,"activeCount":99},[],{"trials":1326,"activeCount":95,"soonestReadout":201},[1327],{"nctId":561,"briefTitle":562,"status":111,"phases":1328,"primaryCompletion":201,"completion":201,"start":564,"enrollment":565,"conditions":1329,"interventions":1330},[87],[306],[568,554],{"trials":1332,"activeCount":99},[],{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[],{"trials":1338,"activeCount":99},[],{"intervention":1340,"totalTrials":435,"cells":1341},"THC",{"EARLY_PHASE1":1342,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1343,"activeCount":95,"soonestReadout":1359},[1344,1355],{"nctId":1345,"briefTitle":1346,"status":478,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1354},"NCT04512365","Reward and Drug Effects on Mood and Brain Response",[86],"2025-05-02","2021-03-16",141,[1352,1353],"Cannabis Use","Healthy",[1340],{"nctId":1356,"briefTitle":1357,"status":261,"phases":1358,"primaryCompletion":1359,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT06758596","Research Investigating Drug Effects-2 (RiDE-2)",[86],"2031-03","2031-06","2026-07-15",144,[1352,1364,1353],"Substance Use Disorder (SUD)",[1340],{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":99},[],{"trials":1371,"activeCount":99},[],{"trials":1373,"activeCount":99},[],{"trials":1375,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1379,"activeCount":95,"soonestReadout":49},[1380],{"nctId":47,"briefTitle":48,"status":111,"phases":1381,"primaryCompletion":49,"completion":1382,"start":1383,"enrollment":409,"conditions":1384,"interventions":1386},[86],"2026-01-01","2018-11-08",[1385],"Pancreatic Cancer",[50,1387],"Saline Solution for",{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[],{"trials":1395,"activeCount":99},[],{"trials":1397,"activeCount":99},[],{"intervention":1387,"totalTrials":95,"cells":1399},{"EARLY_PHASE1":1400,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1412,"NA":1414},{"trials":1401,"activeCount":95,"soonestReadout":49},[1402],{"nctId":47,"briefTitle":48,"status":111,"phases":1403,"primaryCompletion":49,"completion":1382,"start":1383,"enrollment":409,"conditions":1404,"interventions":1405},[86],[1385],[50,1387],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":99},[],{"trials":1413,"activeCount":99},[],{"trials":1415,"activeCount":99},[],{"intervention":452,"totalTrials":435,"cells":1417},{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1432,"PHASE3":1434,"PHASE4":1436,"NA":1438},{"trials":1419,"activeCount":99},[],{"trials":1421,"activeCount":99},[1422],{"nctId":1423,"briefTitle":1424,"status":329,"phases":1425,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":333,"conditions":1428,"interventions":1429},"NCT02132403","(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer",[87],"2015-04","2014-08",[1385],[1430,1431,452],"BTH1704","IMPRIME PGG",{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":99},[],{"trials":1439,"activeCount":95,"soonestReadout":446},[1440],{"nctId":443,"briefTitle":444,"status":111,"phases":1441,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":1442,"interventions":1443},[91],[450],[432,309,452,453,454],{"intervention":1445,"totalTrials":95,"cells":1446},"Dexmedetomidine",{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":99},[],{"trials":1456,"activeCount":99},[],{"trials":1458,"activeCount":95,"soonestReadout":1463},[1459],{"nctId":1460,"briefTitle":1461,"status":111,"phases":1462,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1470},"NCT05736198","Comparison of Two Sedation Regimens for Awake Fiberoptic Intubation",[],"2033-06-15","2034-03-01","2024-08-12",96,[1468,1469],"Awake Fiberoptic Intubation","Difficult Airway",[1445],{"intervention":453,"totalTrials":95,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1474,"activeCount":99},[],{"trials":1476,"activeCount":99},[],{"trials":1478,"activeCount":99},[],{"trials":1480,"activeCount":99},[],{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":95,"soonestReadout":446},[1485],{"nctId":443,"briefTitle":444,"status":111,"phases":1486,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":1487,"interventions":1488},[91],[450],[432,309,452,453,454],{"intervention":454,"totalTrials":95,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1492,"activeCount":99},[],{"trials":1494,"activeCount":99},[],{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[],{"trials":1500,"activeCount":99},[],{"trials":1502,"activeCount":95,"soonestReadout":446},[1503],{"nctId":443,"briefTitle":444,"status":111,"phases":1504,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":1505,"interventions":1506},[91],[450],[432,309,452,453,454],{"intervention":45,"totalTrials":95,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[],{"trials":1518,"activeCount":99},[],{"trials":1520,"activeCount":95,"soonestReadout":44},[1521],{"nctId":42,"briefTitle":43,"status":261,"phases":1522,"primaryCompletion":44,"completion":807,"start":1523,"enrollment":916,"conditions":1524,"interventions":1527},[],"2023-06",[1525,1526],"Male Infertility","Male Hypogonadism",[45],{"intervention":1529,"totalTrials":435,"cells":1530},"Digoxin",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1567},{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[1535],{"nctId":1536,"briefTitle":1537,"status":1538,"phases":1539,"primaryCompletion":1540,"completion":1541,"start":1542,"enrollment":99,"conditions":1543,"interventions":1550},"NCT03433833","Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing","WITHDRAWN",[87],"2024-04-16","2024-12-31","2019-11-10",[1544,1545,1546,1547,1548,1549],"Polycythemia; Familial","Erythrocytosis; Familial","VHL Gene Mutation","HIF-2alpha Erythrocytosis","PHD2 Erythrocytosis","Chuvash Erythrocytosis",[1529],{"trials":1552,"activeCount":99},[],{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":99},[1557],{"nctId":1558,"briefTitle":1559,"status":478,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1566},"NCT01005602","Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care",[90],"2009-12","2006-12",131,[1565],"Heart Failure",[1529],{"trials":1568,"activeCount":99},[],{"intervention":1570,"totalTrials":435,"cells":1571},"Dronabinol",{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1589,"PHASE4":1591,"NA":1603},{"trials":1573,"activeCount":99},[],{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[1578],{"nctId":1579,"briefTitle":1580,"status":478,"phases":1581,"primaryCompletion":1582,"completion":1583,"start":1584,"enrollment":1585,"conditions":1586,"interventions":1588},"NCT01755091","Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea",[88],"2016-06","2016-12-31","2013-02",75,[1587],"Sleep Apnea, Obstructive",[1570],{"trials":1590,"activeCount":99},[],{"trials":1592,"activeCount":99},[1593],{"nctId":1594,"briefTitle":1595,"status":478,"phases":1596,"primaryCompletion":1597,"completion":1597,"start":1598,"enrollment":1599,"conditions":1600,"interventions":1602},"NCT02472847","Cannabinoid Control of Fear Extinction Neural Circuits in Humans",[90],"2014-07","2012-05",85,[1601],"Healthy Participants",[1570],{"trials":1604,"activeCount":99},[],{"intervention":1606,"totalTrials":95,"cells":1607},"Acetaminophen - 4 grams per day + Placebo",{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1614,"PHASE4":1616,"NA":1628},{"trials":1609,"activeCount":99},[],{"trials":1611,"activeCount":99},[],{"trials":1613,"activeCount":99},[],{"trials":1615,"activeCount":99},[],{"trials":1617,"activeCount":99},[1618],{"nctId":1619,"briefTitle":1620,"status":478,"phases":1621,"primaryCompletion":1622,"completion":1622,"start":1562,"enrollment":1623,"conditions":1624,"interventions":1625},"NCT00594867","The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers",[90],"2007-12",94,[1353],[1606,1626,1627],"Aspirin - 325 mg per day + Placebo","Acetaminophen 4 gram per day + Aspirin 325 mg per day",{"trials":1629,"activeCount":99},[],{"intervention":1626,"totalTrials":95,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1646},{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[],{"trials":1639,"activeCount":99},[],{"trials":1641,"activeCount":99},[1642],{"nctId":1619,"briefTitle":1620,"status":478,"phases":1643,"primaryCompletion":1622,"completion":1622,"start":1562,"enrollment":1623,"conditions":1644,"interventions":1645},[90],[1353],[1606,1626,1627],{"trials":1647,"activeCount":99},[],{"intervention":1627,"totalTrials":95,"cells":1649},{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1658,"NA":1664},{"trials":1651,"activeCount":99},[],{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[],{"trials":1659,"activeCount":99},[1660],{"nctId":1619,"briefTitle":1620,"status":478,"phases":1661,"primaryCompletion":1622,"completion":1622,"start":1562,"enrollment":1623,"conditions":1662,"interventions":1663},[90],[1353],[1606,1626,1627],{"trials":1665,"activeCount":99},[],{"intervention":1667,"totalTrials":95,"cells":1668},"Telithromycin",{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1675,"PHASE4":1677,"NA":1689},{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[],{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[1679],{"nctId":1680,"briefTitle":1681,"status":329,"phases":1682,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1687},"NCT00315601","Intrapulmonary Pharmacokinetics of Antibiotics",[90],"2006-11","2006-01",35,[1353],[1667,1688,1667],"azithromycin",{"trials":1690,"activeCount":99},[],{"intervention":1688,"totalTrials":95,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1707},{"trials":1694,"activeCount":99},[],{"trials":1696,"activeCount":99},[],{"trials":1698,"activeCount":99},[],{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[1703],{"nctId":1680,"briefTitle":1681,"status":329,"phases":1704,"primaryCompletion":1683,"completion":1683,"start":1684,"enrollment":1685,"conditions":1705,"interventions":1706},[90],[1353],[1667,1688,1667],{"trials":1708,"activeCount":99},[],{"intervention":1710,"totalTrials":95,"cells":1711},"Stimulant or sedative",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1732},{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[],{"trials":1717,"activeCount":99},[],{"trials":1719,"activeCount":99},[],{"trials":1721,"activeCount":99},[1722],{"nctId":1723,"briefTitle":1724,"status":478,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":1728,"conditions":1729,"interventions":1731},"NCT03075501","Interactions Between Drug Effects and Environments II",[90],"2020-07","2015-11",133,[1730],"Substance-Related Disorders",[1710],{"trials":1733,"activeCount":99},[],{"intervention":1735,"totalTrials":95,"cells":1736},"Transdermal Estradiol + Placebo",{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1743,"PHASE4":1745,"NA":1758},{"trials":1738,"activeCount":99},[],{"trials":1740,"activeCount":99},[],{"trials":1742,"activeCount":99},[],{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[1747],{"nctId":1748,"briefTitle":1749,"status":478,"phases":1750,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":981,"conditions":1753,"interventions":1755},"NCT03498313","Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality",[90],"2021-05-09","2018-07-27",[1754],"Suicidal Ideation",[1735,1756,1757],"Oral Micronized Progesterone + Placebo","Placebos",{"trials":1759,"activeCount":99},[],{"intervention":1756,"totalTrials":95,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1776},{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":99},[],{"trials":1767,"activeCount":99},[],{"trials":1769,"activeCount":99},[],{"trials":1771,"activeCount":99},[1772],{"nctId":1748,"briefTitle":1749,"status":478,"phases":1773,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":981,"conditions":1774,"interventions":1775},[90],[1754],[1735,1756,1757],{"trials":1777,"activeCount":99},[],{"intervention":1757,"totalTrials":95,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1794},{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[],{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[],{"trials":1789,"activeCount":99},[1790],{"nctId":1748,"briefTitle":1749,"status":478,"phases":1791,"primaryCompletion":1751,"completion":1751,"start":1752,"enrollment":981,"conditions":1792,"interventions":1793},[90],[1754],[1735,1756,1757],{"trials":1795,"activeCount":99},[],{"intervention":487,"totalTrials":95,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1812},{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[],{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[1808],{"nctId":476,"briefTitle":477,"status":478,"phases":1809,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1810,"interventions":1811},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1813,"activeCount":99},[],{"intervention":488,"totalTrials":95,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1830},{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[],{"trials":1821,"activeCount":99},[],{"trials":1823,"activeCount":99},[],{"trials":1825,"activeCount":99},[1826],{"nctId":476,"briefTitle":477,"status":478,"phases":1827,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1828,"interventions":1829},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1831,"activeCount":99},[],{"intervention":489,"totalTrials":95,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1848},{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"trials":1839,"activeCount":99},[],{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[1844],{"nctId":476,"briefTitle":477,"status":478,"phases":1845,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1846,"interventions":1847},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1849,"activeCount":99},[],{"intervention":490,"totalTrials":95,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1858,"PHASE4":1860,"NA":1866},{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[],{"trials":1857,"activeCount":99},[],{"trials":1859,"activeCount":99},[],{"trials":1861,"activeCount":99},[1862],{"nctId":476,"briefTitle":477,"status":478,"phases":1863,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1864,"interventions":1865},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1867,"activeCount":99},[],{"intervention":491,"totalTrials":95,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1878,"NA":1884},{"trials":1871,"activeCount":99},[],{"trials":1873,"activeCount":99},[],{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":99},[],{"trials":1879,"activeCount":99},[1880],{"nctId":476,"briefTitle":477,"status":478,"phases":1881,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1882,"interventions":1883},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1885,"activeCount":99},[],{"intervention":492,"totalTrials":95,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1894,"PHASE4":1896,"NA":1902},{"trials":1889,"activeCount":99},[],{"trials":1891,"activeCount":99},[],{"trials":1893,"activeCount":99},[],{"trials":1895,"activeCount":99},[],{"trials":1897,"activeCount":99},[1898],{"nctId":476,"briefTitle":477,"status":478,"phases":1899,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1900,"interventions":1901},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1903,"activeCount":99},[],{"intervention":493,"totalTrials":95,"cells":1905},{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1920},{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[],{"trials":1913,"activeCount":99},[],{"trials":1915,"activeCount":99},[1916],{"nctId":476,"briefTitle":477,"status":478,"phases":1917,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1918,"interventions":1919},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1921,"activeCount":99},[],{"intervention":494,"totalTrials":95,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1938},{"trials":1925,"activeCount":99},[],{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[1934],{"nctId":476,"briefTitle":477,"status":478,"phases":1935,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1936,"interventions":1937},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1939,"activeCount":99},[],{"intervention":495,"totalTrials":95,"cells":1941},{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1948,"PHASE4":1950,"NA":1956},{"trials":1943,"activeCount":99},[],{"trials":1945,"activeCount":99},[],{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":99},[],{"trials":1951,"activeCount":99},[1952],{"nctId":476,"briefTitle":477,"status":478,"phases":1953,"primaryCompletion":480,"completion":481,"start":482,"enrollment":483,"conditions":1954,"interventions":1955},[90],[485],[487,487,488,489,490,491,492,493,494,354,495],{"trials":1957,"activeCount":99},[],{"intervention":1959,"totalTrials":95,"cells":1960},"tacrolimus extended release",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1967,"PHASE4":1969,"NA":1981},{"trials":1962,"activeCount":99},[],{"trials":1964,"activeCount":99},[],{"trials":1966,"activeCount":99},[],{"trials":1968,"activeCount":99},[],{"trials":1970,"activeCount":99},[1971],{"nctId":1972,"briefTitle":1973,"status":478,"phases":1974,"primaryCompletion":1975,"completion":1976,"start":1977,"enrollment":1128,"conditions":1978,"interventions":1980},"NCT02444143","A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients",[90],"2017-02-28","2017-06-09","2015-05",[1979],"Kidney Transplantation",[1959],{"trials":1982,"activeCount":99},[],{"intervention":1984,"totalTrials":95,"cells":1985},"Acthar",{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1992,"PHASE4":1994,"NA":2007},{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[],{"trials":1995,"activeCount":99},[1996],{"nctId":1997,"briefTitle":1998,"status":329,"phases":1999,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":435,"conditions":2003,"interventions":2006},"NCT02057523","Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients",[90],"2015-03","2015-09","2014-09",[2004,2005],"Proteinuria","Transplant Glomerulopathy",[1984],{"trials":2008,"activeCount":99},[],{"intervention":2010,"totalTrials":95,"cells":2011},"SSRI",{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2016,"PHASE3":2018,"PHASE4":2020,"NA":2032},{"trials":2013,"activeCount":99},[],{"trials":2015,"activeCount":99},[],{"trials":2017,"activeCount":99},[],{"trials":2019,"activeCount":99},[],{"trials":2021,"activeCount":99},[2022],{"nctId":2023,"briefTitle":2024,"status":478,"phases":2025,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2031},"NCT01903447","Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment",[90],"2018-02-21","2013-12-13",271,[2030],"Internalizing Psychopathologies (IPs) Depression and Anxiety",[2010],{"trials":2033,"activeCount":99},[],{"intervention":2035,"totalTrials":95,"cells":2036},"OROS methylphenidate",{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2057},{"trials":2038,"activeCount":99},[],{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[],{"trials":2044,"activeCount":99},[],{"trials":2046,"activeCount":99},[2047],{"nctId":2048,"briefTitle":2049,"status":478,"phases":2050,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":2053,"conditions":2054,"interventions":2056},"NCT00663442","Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)",[90],"2004-11","1999-12",48,[2055],"ADHD",[2035],{"trials":2058,"activeCount":99},[],{"intervention":2060,"totalTrials":95,"cells":2061},"2% dorzolamide",{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2066,"PHASE3":2068,"PHASE4":2070,"NA":2083},{"trials":2063,"activeCount":99},[],{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"trials":2069,"activeCount":99},[],{"trials":2071,"activeCount":99},[2072],{"nctId":2073,"briefTitle":2074,"status":478,"phases":2075,"primaryCompletion":2076,"completion":2077,"start":2078,"enrollment":2079,"conditions":2080,"interventions":2082},"NCT00716586","Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration",[90],"2015-08-11","2017-11-17","2005-10",44,[2081],"Retinal Degenerations",[2060],{"trials":2084,"activeCount":99},[],{"intervention":2086,"totalTrials":95,"cells":2087},"Estradiol Transdermal Patch 0.1 mg\u002F24 hrs",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2096,"NA":2109},{"trials":2089,"activeCount":99},[],{"trials":2091,"activeCount":99},[],{"trials":2093,"activeCount":99},[],{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[2098],{"nctId":2099,"briefTitle":2100,"status":478,"phases":2101,"primaryCompletion":2102,"completion":2102,"start":2103,"enrollment":2104,"conditions":2105,"interventions":2106},"NCT04112368","Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach",[90],"2024-08-01","2020-09-15",124,[1754],[2086,2107,2108],"Oral Micronized Progesterone 200mg","Inactive Clear Patch",{"trials":2110,"activeCount":99},[],{"intervention":2107,"totalTrials":95,"cells":2112},{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2119,"PHASE4":2121,"NA":2127},{"trials":2114,"activeCount":99},[],{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[],{"trials":2120,"activeCount":99},[],{"trials":2122,"activeCount":99},[2123],{"nctId":2099,"briefTitle":2100,"status":478,"phases":2124,"primaryCompletion":2102,"completion":2102,"start":2103,"enrollment":2104,"conditions":2125,"interventions":2126},[90],[1754],[2086,2107,2108],{"trials":2128,"activeCount":99},[],{"intervention":2108,"totalTrials":95,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2145},{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[2141],{"nctId":2099,"briefTitle":2100,"status":478,"phases":2142,"primaryCompletion":2102,"completion":2102,"start":2103,"enrollment":2104,"conditions":2143,"interventions":2144},[90],[1754],[2086,2107,2108],{"trials":2146,"activeCount":99},[],{"intervention":2148,"totalTrials":95,"cells":2149},"Angiotensin II",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2156,"PHASE4":2158,"NA":2174},{"trials":2151,"activeCount":99},[],{"trials":2153,"activeCount":99},[],{"trials":2155,"activeCount":99},[],{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[2160],{"nctId":2161,"briefTitle":2162,"status":478,"phases":2163,"primaryCompletion":2164,"completion":2164,"start":2165,"enrollment":1128,"conditions":2166,"interventions":2173},"NCT04529005","Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients",[90],"2021-08-01","2020-08-13",[2167,2168,2169,2170,2171,2172],"Shock, Surgical","Shock","Hypotension and Shock","Kidney Transplant; Complications","Intraoperative Hypotension","Postoperative Hypotension",[2148],{"trials":2175,"activeCount":99},[],{"intervention":2177,"totalTrials":95,"cells":2178},"Imipenem\u002FCilastatin\u002FRelebactam 1.25g",{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2185,"PHASE4":2187,"NA":2199},{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[],{"trials":2184,"activeCount":99},[],{"trials":2186,"activeCount":99},[],{"trials":2188,"activeCount":99},[2189],{"nctId":2190,"briefTitle":2191,"status":1538,"phases":2192,"primaryCompletion":2193,"completion":2194,"start":2195,"enrollment":99,"conditions":2196,"interventions":2198},"NCT05146154","Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients",[90],"2023-06-01","2024-01-01","2023-01-01",[15,2197],"Critical Illness",[2177],{"trials":2200,"activeCount":99},[],{"intervention":2202,"totalTrials":95,"cells":2203},"Typhoid Vaccine",{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2212,"NA":2224},{"trials":2205,"activeCount":99},[],{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[2214],{"nctId":2215,"briefTitle":2216,"status":329,"phases":2217,"primaryCompletion":2218,"completion":2218,"start":2219,"enrollment":1685,"conditions":2220,"interventions":2223},"NCT03889158","Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation",[90],"2020-03-13","2019-03-25",[2221,2222],"Aging","Inflammation",[2202],{"trials":2225,"activeCount":99},[],{"intervention":2227,"totalTrials":95,"cells":2228},"Screening for diabetes with 1-hour GCT and HbA1",{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2235,"PHASE4":2247,"NA":2249},{"trials":2230,"activeCount":99},[],{"trials":2232,"activeCount":99},[],{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[2237],{"nctId":2238,"briefTitle":2239,"status":329,"phases":2240,"primaryCompletion":2241,"completion":2241,"start":2242,"enrollment":2243,"conditions":2244,"interventions":2246},"NCT03116009","Randomization of Early Diabetes Screening Among Obese Pregnant Women.",[89],"2019-11-25","2017-03-19",600,[2245],"Gestational Diabetes",[2227],{"trials":2248,"activeCount":99},[],{"trials":2250,"activeCount":99},[],{"intervention":2252,"totalTrials":95,"cells":2253},"Albuterol",{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2272,"NA":2274},{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":99},[2262],{"nctId":2263,"briefTitle":2264,"status":478,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2271},"NCT03137303","Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)",[89],"2019-09-30","2017-07-01",402,[2270],"COPD Asthma",[2252],{"trials":2273,"activeCount":99},[],{"trials":2275,"activeCount":99},[],{"intervention":2277,"totalTrials":95,"cells":2278},"Cannabidiol",{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2283,"PHASE3":2285,"PHASE4":2298,"NA":2300},{"trials":2280,"activeCount":99},[],{"trials":2282,"activeCount":99},[],{"trials":2284,"activeCount":99},[],{"trials":2286,"activeCount":99},[2287],{"nctId":2288,"briefTitle":2289,"status":1538,"phases":2290,"primaryCompletion":2291,"completion":2291,"start":2292,"enrollment":99,"conditions":2293,"interventions":2297},"NCT03467620","Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease",[88,89],"2019-07","2018-07",[2294,2295,2296],"Crohn Disease","Inflammatory Bowel Diseases","Cannabis",[2277],{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[],{"intervention":2303,"totalTrials":95,"cells":2304},"Risperdal Consta",{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2309,"PHASE3":2311,"PHASE4":2324,"NA":2326},{"trials":2306,"activeCount":99},[],{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[2313],{"nctId":2314,"briefTitle":2315,"status":478,"phases":2316,"primaryCompletion":2317,"completion":2317,"start":2318,"enrollment":2319,"conditions":2320,"interventions":2323},"NCT00148083","Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia",[89],"2006-03","2005-09",5,[2321,2322],"Schizophrenia","Schizoaffective Disorder",[2303],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"intervention":2329,"totalTrials":95,"cells":2330},"Arabin Pessary",{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2350,"NA":2352},{"trials":2332,"activeCount":99},[],{"trials":2334,"activeCount":99},[],{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[2339],{"nctId":2340,"briefTitle":2341,"status":329,"phases":2342,"primaryCompletion":2343,"completion":2343,"start":2344,"enrollment":2345,"conditions":2346,"interventions":2349},"NCT03052270","Arabin Pessary Combine With Vaginal Progesterone Compare With Vaginal Progesterone Alone to Prevent Preterm Delivery in Singleton Pregnancies",[89],"2019-12-23","2017-01",57,[2347,2348],"Focus: Prevent Preterm Delivery","Incidental Short Cervix at Mid-trimester",[2329],{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":99},[],{"intervention":2355,"totalTrials":95,"cells":2356},"Divalproex Sodium",{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2361,"PHASE3":2363,"PHASE4":2376,"NA":2378},{"trials":2358,"activeCount":99},[],{"trials":2360,"activeCount":99},[],{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[2365],{"nctId":2366,"briefTitle":2367,"status":478,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2374},"NCT00176202","Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar",[89],"2008-01","2003-04",65,[2373],"Bipolar Disorder",[2355,2375],"risperidone",{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"intervention":2375,"totalTrials":95,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2394,"NA":2396},{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":99},[],{"trials":2389,"activeCount":99},[2390],{"nctId":2366,"briefTitle":2367,"status":478,"phases":2391,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2392,"interventions":2393},[89],[2373],[2355,2375],{"trials":2395,"activeCount":99},[],{"trials":2397,"activeCount":99},[],{"intervention":2399,"totalTrials":435,"cells":2400},"ranibizumab",{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2405,"PHASE3":2429,"PHASE4":2431,"NA":2433},{"trials":2402,"activeCount":99},[],{"trials":2404,"activeCount":99},[],{"trials":2406,"activeCount":99},[2407,2416],{"nctId":2408,"briefTitle":2409,"status":1538,"phases":2410,"primaryCompletion":2411,"completion":2412,"start":1561,"enrollment":99,"conditions":2413,"interventions":2415},"NCT01015495","Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks",[87,88],"2010-12","2011-01",[2414],"Angioid Streaks",[2399],{"nctId":2417,"briefTitle":2418,"status":1538,"phases":2419,"primaryCompletion":2420,"completion":2420,"start":2421,"enrollment":99,"conditions":2422,"interventions":2427},"NCT00727038","Lucentis for New Onset Neovascular Glaucoma",[87,88],"2009-05-15","2008-01-04",[2423,2424,2425,2426],"Glaucoma","New Onset Glaucoma","Neovascular Glaucoma","New Onset Neovascular Glaucoma",[2428],"Ranibizumab",{"trials":2430,"activeCount":99},[],{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[],{"intervention":291,"totalTrials":435,"cells":2436},{"EARLY_PHASE1":2437,"PHASE1":2439,"PHASE2":2445,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2438,"activeCount":99},[],{"trials":2440,"activeCount":99},[2441],{"nctId":283,"briefTitle":284,"status":285,"phases":2442,"start":287,"enrollment":288,"conditions":2443,"interventions":2444},[87],[29],[291,292,293,294,295],{"trials":2446,"activeCount":99},[2447],{"nctId":2448,"briefTitle":2449,"status":478,"phases":2450,"completion":2451,"start":2452,"conditions":2453,"interventions":2455},"NCT00003568","Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma",[88],"2005-12","1998-11",[2454],"Melanoma (Skin)",[291,2456,2457],"gp100 antigen","incomplete Freund's adjuvant",{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"intervention":2465,"totalTrials":435,"cells":2466},"Vehicle",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2493,"PHASE4":2495,"NA":2497},{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[2473,2484],{"nctId":2474,"briefTitle":2475,"status":329,"phases":2476,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":11,"conditions":2479,"interventions":2482},"NCT02702518","rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease",[87,88],"2020-04-08","2016-04",[2480,2481],"Ocular Graft vs Host Disease","Dry Eye",[2483,2465],"rhDNase I",{"nctId":2485,"briefTitle":2486,"status":329,"phases":2487,"primaryCompletion":2488,"completion":2488,"start":1597,"enrollment":2489,"conditions":2490,"interventions":2491},"NCT02193490","DNase Treatment for Dry Eyes",[87,88],"2017-10-11",47,[2481],[2492,2465],"DNase",{"trials":2494,"activeCount":99},[],{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[],{"intervention":2500,"totalTrials":95,"cells":2501},"Vitamin D3",{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2518,"PHASE4":2520,"NA":2522},{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[],{"trials":2507,"activeCount":99},[2508],{"nctId":2509,"briefTitle":2510,"status":478,"phases":2511,"primaryCompletion":2512,"completion":2512,"start":2513,"enrollment":2514,"conditions":2515,"interventions":2517},"NCT01574027","Efficacy of Vitamin D in Colorectal Cancer Chemoprevention",[88],"2011-10","2008-04",55,[2516],"Colorectal Cancer",[2500],{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[],{"intervention":2525,"totalTrials":95,"cells":2526},"IBI-20089\u002FLucentis",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[],{"trials":2532,"activeCount":99},[2533],{"nctId":2534,"briefTitle":2535,"status":478,"phases":2536,"primaryCompletion":2537,"completion":2537,"start":2538,"enrollment":32,"conditions":2539,"interventions":2542},"NCT01175395","20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)",[87,88],"2013-01","2010-09",[2540,2541],"Age-Related Macular Degeneration","Choroidal Neovascularization",[2525],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"intervention":2550,"totalTrials":95,"cells":2551},"d-amphetamine",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2568,"PHASE4":2570,"NA":2572},{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":99},[],{"trials":2557,"activeCount":99},[2558],{"nctId":2559,"briefTitle":2560,"status":478,"phases":2561,"primaryCompletion":2562,"completion":2562,"start":2563,"enrollment":2345,"conditions":2564,"interventions":2567},"NCT02773212","Targeting Anhedonia in Cocaine Use Disorder",[88],"2022-04-04","2017-02-01",[2565,2566],"Cocaine-Related Disorders","Anhedonia",[2550],{"trials":2569,"activeCount":99},[],{"trials":2571,"activeCount":99},[],{"trials":2573,"activeCount":99},[],{"intervention":415,"totalTrials":95,"cells":2575},{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2577,"activeCount":99},[],{"trials":2579,"activeCount":99},[],{"trials":2581,"activeCount":99},[2582],{"nctId":405,"briefTitle":406,"status":285,"phases":2583,"start":408,"enrollment":409,"conditions":2584,"interventions":2585},[87,88],[411,412,413],[415,416,417],{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"intervention":416,"totalTrials":95,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2604,"PHASE4":2606,"NA":2608},{"trials":2595,"activeCount":99},[],{"trials":2597,"activeCount":99},[],{"trials":2599,"activeCount":99},[2600],{"nctId":405,"briefTitle":406,"status":285,"phases":2601,"start":408,"enrollment":409,"conditions":2602,"interventions":2603},[87,88],[411,412,413],[415,416,417],{"trials":2605,"activeCount":99},[],{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"intervention":2611,"totalTrials":95,"cells":2612},"Lamotrigine",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[2619],{"nctId":2620,"briefTitle":2621,"status":478,"phases":2622,"primaryCompletion":2369,"completion":2369,"start":2623,"enrollment":2053,"conditions":2624,"interventions":2625},"NCT00176228","Lamotrigine Monotherapy in Pediatric Bipolar Disorder",[88],"2004-02",[2373],[2611],{"trials":2627,"activeCount":99},[],{"trials":2629,"activeCount":99},[],{"trials":2631,"activeCount":99},[],{"intervention":2633,"totalTrials":95,"cells":2634},"Transdermal Estradiol",{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2639,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2636,"activeCount":99},[],{"trials":2638,"activeCount":99},[],{"trials":2640,"activeCount":99},[2641],{"nctId":2642,"briefTitle":2643,"status":329,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":25,"conditions":2647,"interventions":2649},"NCT06191289","Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality",[88],"2024-12-01","2024-03-16",[2648],"Suicide",[2633],{"trials":2651,"activeCount":99},[],{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[],{"intervention":2657,"totalTrials":95,"cells":2658},"Carbon Monoxide",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":99},[],{"trials":2664,"activeCount":99},[2665],{"nctId":2666,"briefTitle":2667,"status":1538,"phases":2668,"primaryCompletion":2669,"completion":2669,"start":2670,"enrollment":99,"conditions":2671,"interventions":2673},"NCT01523548","Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension",[87,88],"2018-12","2012-07",[2672],"Hypertension, Pulmonary",[2657],{"trials":2675,"activeCount":99},[],{"trials":2677,"activeCount":99},[],{"trials":2679,"activeCount":99},[],{"intervention":2681,"totalTrials":95,"cells":2682},"Cytarabine",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2684,"activeCount":99},[],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[2689],{"nctId":2690,"briefTitle":2691,"status":329,"phases":2692,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":19,"conditions":2695,"interventions":2696},"NCT02440568","AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients",[87,88],"2018-11-30","2015-06-05",[375],[2681,2697,2698,2698,2698,2698],"Idarubicin","Omacetaxine mepesuccinate",{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[],{"intervention":2697,"totalTrials":95,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2711,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2708,"activeCount":99},[],{"trials":2710,"activeCount":99},[],{"trials":2712,"activeCount":99},[2713],{"nctId":2690,"briefTitle":2691,"status":329,"phases":2714,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":19,"conditions":2715,"interventions":2716},[87,88],[375],[2681,2697,2698,2698,2698,2698],{"trials":2718,"activeCount":99},[],{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[],{"intervention":2698,"totalTrials":95,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2729,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":99},[],{"trials":2730,"activeCount":99},[2731],{"nctId":2690,"briefTitle":2691,"status":329,"phases":2732,"primaryCompletion":2693,"completion":2693,"start":2694,"enrollment":19,"conditions":2733,"interventions":2734},[87,88],[375],[2681,2697,2698,2698,2698,2698],{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"trials":2740,"activeCount":99},[],{"intervention":2456,"totalTrials":95,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[2749],{"nctId":2448,"briefTitle":2449,"status":478,"phases":2750,"completion":2451,"start":2452,"conditions":2751,"interventions":2752},[88],[2454],[291,2456,2457],{"trials":2754,"activeCount":99},[],{"trials":2756,"activeCount":99},[],{"trials":2758,"activeCount":99},[],{"intervention":2457,"totalTrials":95,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":99},[],{"trials":2764,"activeCount":99},[],{"trials":2766,"activeCount":99},[2767],{"nctId":2448,"briefTitle":2449,"status":478,"phases":2768,"completion":2451,"start":2452,"conditions":2769,"interventions":2770},[88],[2454],[291,2456,2457],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[],{"intervention":2778,"totalTrials":95,"cells":2779},"Oral Rehydration Solution 1",{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2800,"PHASE4":2802,"NA":2804},{"trials":2781,"activeCount":99},[],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":99},[2786],{"nctId":2787,"briefTitle":2788,"status":478,"phases":2789,"primaryCompletion":2790,"completion":2791,"start":2792,"enrollment":2793,"conditions":2794,"interventions":2798},"NCT05111392","Hydration Dynamics and Influence of Beverage Composition",[87,88],"2022-10-31","2022-11-30","2021-09-03",14,[2795,2796,2797],"Hydration","Fluid Retention","Dehydration",[2778,2799],"Oral Rehydration Solution 2",{"trials":2801,"activeCount":99},[],{"trials":2803,"activeCount":99},[],{"trials":2805,"activeCount":99},[],{"intervention":2799,"totalTrials":95,"cells":2807},{"EARLY_PHASE1":2808,"PHASE1":2810,"PHASE2":2812,"PHASE3":2818,"PHASE4":2820,"NA":2822},{"trials":2809,"activeCount":99},[],{"trials":2811,"activeCount":99},[],{"trials":2813,"activeCount":99},[2814],{"nctId":2787,"briefTitle":2788,"status":478,"phases":2815,"primaryCompletion":2790,"completion":2791,"start":2792,"enrollment":2793,"conditions":2816,"interventions":2817},[87,88],[2795,2796,2797],[2778,2799],{"trials":2819,"activeCount":99},[],{"trials":2821,"activeCount":99},[],{"trials":2823,"activeCount":99},[],{"intervention":2825,"totalTrials":95,"cells":2826},"Estradiol",{"EARLY_PHASE1":2827,"PHASE1":2829,"PHASE2":2831,"PHASE3":2844,"PHASE4":2846,"NA":2848},{"trials":2828,"activeCount":99},[],{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[2833],{"nctId":2834,"briefTitle":2835,"status":478,"phases":2836,"primaryCompletion":1977,"completion":1977,"start":1561,"enrollment":1466,"conditions":2837,"interventions":2840},"NCT00997893","Research Investigation of Soy and Estrogen",[88],[2838,2839],"Menopause","Hot Flashes",[2825,2841,2842,2843],"Medroxyprogesterone Acetate","Soy Placebo","MPA Placebo",{"trials":2845,"activeCount":99},[],{"trials":2847,"activeCount":99},[],{"trials":2849,"activeCount":99},[],{"intervention":2841,"totalTrials":95,"cells":2851},{"EARLY_PHASE1":2852,"PHASE1":2854,"PHASE2":2856,"PHASE3":2862,"PHASE4":2864,"NA":2866},{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[2858],{"nctId":2834,"briefTitle":2835,"status":478,"phases":2859,"primaryCompletion":1977,"completion":1977,"start":1561,"enrollment":1466,"conditions":2860,"interventions":2861},[88],[2838,2839],[2825,2841,2842,2843],{"trials":2863,"activeCount":99},[],{"trials":2865,"activeCount":99},[],{"trials":2867,"activeCount":99},[],{"intervention":2842,"totalTrials":95,"cells":2869},{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2871,"activeCount":99},[],{"trials":2873,"activeCount":99},[],{"trials":2875,"activeCount":99},[2876],{"nctId":2834,"briefTitle":2835,"status":478,"phases":2877,"primaryCompletion":1977,"completion":1977,"start":1561,"enrollment":1466,"conditions":2878,"interventions":2879},[88],[2838,2839],[2825,2841,2842,2843],{"trials":2881,"activeCount":99},[],{"trials":2883,"activeCount":99},[],{"trials":2885,"activeCount":99},[],{"intervention":2843,"totalTrials":95,"cells":2887},{"EARLY_PHASE1":2888,"PHASE1":2890,"PHASE2":2892,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2889,"activeCount":99},[],{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[2894],{"nctId":2834,"briefTitle":2835,"status":478,"phases":2895,"primaryCompletion":1977,"completion":1977,"start":1561,"enrollment":1466,"conditions":2896,"interventions":2897},[88],[2838,2839],[2825,2841,2842,2843],{"trials":2899,"activeCount":99},[],{"trials":2901,"activeCount":99},[],{"trials":2903,"activeCount":99},[],{"intervention":2905,"totalTrials":95,"cells":2906},"20% betulinic acid ointment",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2911,"PHASE3":2922,"PHASE4":2924,"NA":2926},{"trials":2908,"activeCount":99},[],{"trials":2910,"activeCount":99},[],{"trials":2912,"activeCount":99},[2913],{"nctId":2914,"briefTitle":2915,"status":1538,"phases":2916,"primaryCompletion":2917,"completion":2917,"start":1684,"enrollment":99,"conditions":2918,"interventions":2920},"NCT00346502","Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)",[87,88],"2015-12",[2919],"Dysplastic Nevus Syndrome",[2905,2921],"BA",{"trials":2923,"activeCount":99},[],{"trials":2925,"activeCount":99},[],{"trials":2927,"activeCount":99},[],{"intervention":2921,"totalTrials":95,"cells":2929},{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[],{"trials":2935,"activeCount":99},[2936],{"nctId":2914,"briefTitle":2915,"status":1538,"phases":2937,"primaryCompletion":2917,"completion":2917,"start":1684,"enrollment":99,"conditions":2938,"interventions":2939},[87,88],[2919],[2905,2921],{"trials":2941,"activeCount":99},[],{"trials":2943,"activeCount":99},[],{"trials":2945,"activeCount":99},[],{"intervention":2947,"totalTrials":95,"cells":2948},"Novolin R",{"EARLY_PHASE1":2949,"PHASE1":2951,"PHASE2":2953,"PHASE3":2964,"PHASE4":2966,"NA":2968},{"trials":2950,"activeCount":99},[],{"trials":2952,"activeCount":99},[],{"trials":2954,"activeCount":99},[2955],{"nctId":2956,"briefTitle":2957,"status":329,"phases":2958,"primaryCompletion":2959,"completion":2959,"start":2960,"enrollment":356,"conditions":2961,"interventions":2963},"NCT03811951","Neuro Biomarkers of Smoking Behavior",[88],"2019-09-27","2018-09-12",[2962],"Smoking Cessation",[2947],{"trials":2965,"activeCount":99},[],{"trials":2967,"activeCount":99},[],{"trials":2969,"activeCount":99},[],{"intervention":2483,"totalTrials":95,"cells":2971},{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2982,"PHASE4":2984,"NA":2986},{"trials":2973,"activeCount":99},[],{"trials":2975,"activeCount":99},[],{"trials":2977,"activeCount":99},[2978],{"nctId":2474,"briefTitle":2475,"status":329,"phases":2979,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":11,"conditions":2980,"interventions":2981},[87,88],[2480,2481],[2483,2465],{"trials":2983,"activeCount":99},[],{"trials":2985,"activeCount":99},[],{"trials":2987,"activeCount":99},[],{"intervention":2989,"totalTrials":95,"cells":2990},"Islet Cell Transplant",{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":3007,"PHASE4":3009,"NA":3011},{"trials":2992,"activeCount":99},[],{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[2997],{"nctId":2998,"briefTitle":2999,"status":478,"phases":3000,"primaryCompletion":3001,"completion":3002,"start":2051,"enrollment":32,"conditions":3003,"interventions":3005},"NCT00566813","Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression",[87,88],"2010-07-05","2020-07-15",[3004],"Diabetes Mellitus, Type 1",[2989,3006],"Islet Cell Transplant plus",{"trials":3008,"activeCount":99},[],{"trials":3010,"activeCount":99},[],{"trials":3012,"activeCount":99},[],{"intervention":3006,"totalTrials":95,"cells":3014},{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3025,"PHASE4":3027,"NA":3029},{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[3021],{"nctId":2998,"briefTitle":2999,"status":478,"phases":3022,"primaryCompletion":3001,"completion":3002,"start":2051,"enrollment":32,"conditions":3023,"interventions":3024},[87,88],[3004],[2989,3006],{"trials":3026,"activeCount":99},[],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[],{"intervention":3032,"totalTrials":95,"cells":3033},"Ocular Surface Immune Globulin",{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3035,"activeCount":99},[],{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[3040],{"nctId":3041,"briefTitle":3042,"status":1538,"phases":3043,"primaryCompletion":3044,"completion":3045,"start":3046,"enrollment":99,"conditions":3047,"interventions":3048},"NCT04510428","OSIG-eye Drops Treatment for Dry Eye Disease",[88],"2023-11-30","2024-01-20","2023-05-15",[2481],[3032],{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":99},[],{"trials":3054,"activeCount":99},[],{"intervention":3056,"totalTrials":95,"cells":3057},"Omega-3-acid ethyl esters",{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3062,"PHASE3":3073,"PHASE4":3075,"NA":3077},{"trials":3059,"activeCount":99},[],{"trials":3061,"activeCount":99},[],{"trials":3063,"activeCount":99},[3064],{"nctId":3065,"briefTitle":3066,"status":329,"phases":3067,"primaryCompletion":3068,"completion":3068,"start":2317,"enrollment":565,"conditions":3069,"interventions":3072},"NCT00845845","Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)",[88],"2010-10",[3070,3071],"Nonalcoholic Steatohepatitis (NASH)","Hepatic Steatosis",[3056],{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[],{"trials":3078,"activeCount":99},[],{"intervention":3080,"totalTrials":95,"cells":3081},"Salsalate",{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3086,"PHASE3":3098,"PHASE4":3100,"NA":3102},{"trials":3083,"activeCount":99},[],{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[3088],{"nctId":3089,"briefTitle":3090,"status":478,"phases":3091,"primaryCompletion":3092,"completion":3093,"start":3094,"enrollment":981,"conditions":3095,"interventions":3097},"NCT03229408","Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction",[88],"2024-02-14","2024-02-28","2018-12-05",[3096],"Polycystic Ovary Syndrome",[3080],{"trials":3099,"activeCount":99},[],{"trials":3101,"activeCount":99},[],{"trials":3103,"activeCount":99},[],{"intervention":3105,"totalTrials":95,"cells":3106},"aprepitant, ondansetron, dexamethasone",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3124,"PHASE4":3126,"NA":3128},{"trials":3108,"activeCount":99},[],{"trials":3110,"activeCount":99},[],{"trials":3112,"activeCount":99},[3113],{"nctId":3114,"briefTitle":3115,"status":478,"phases":3116,"primaryCompletion":3117,"completion":3118,"start":3119,"enrollment":19,"conditions":3120,"interventions":3123},"NCT00711555","Emend for Multiple-day Emetogenic Chemotherapy",[88],"2008-11","2009-01","2005-11",[3121,3122],"Nausea","Vomiting",[3105],{"trials":3125,"activeCount":99},[],{"trials":3127,"activeCount":99},[],{"trials":3129,"activeCount":99},[],{"intervention":3131,"totalTrials":95,"cells":3132},"Voxelotor",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":99},[],{"trials":3138,"activeCount":99},[3139],{"nctId":3140,"briefTitle":3141,"status":329,"phases":3142,"primaryCompletion":3143,"completion":3143,"start":1349,"enrollment":565,"conditions":3144,"interventions":3146},"NCT04335721","A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease",[87,88],"2024-10-07",[24,3145],"Sickle Cell Nephropathy",[3131],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":99},[],{"intervention":3154,"totalTrials":95,"cells":3155},"Lycopene 30mg",{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3157,"activeCount":99},[],{"trials":3159,"activeCount":99},[],{"trials":3161,"activeCount":99},[3162],{"nctId":3163,"briefTitle":3164,"status":478,"phases":3165,"primaryCompletion":3166,"completion":3166,"start":3167,"enrollment":3168,"conditions":3169,"interventions":3172},"NCT01443026","The Effects of Lycopene on High Risk Prostatic Tissue",[88],"2009-04","2006-02",66,[3170,3171],"Intraepithelial Prostatic Neoplasia","Prostatic Neoplasms",[3154],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[],{"intervention":3180,"totalTrials":95,"cells":3181},"Lanthanum Carbonate Chewable Product",{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3183,"activeCount":99},[],{"trials":3185,"activeCount":99},[],{"trials":3187,"activeCount":99},[3188],{"nctId":3189,"briefTitle":3190,"status":478,"phases":3191,"primaryCompletion":3192,"completion":3192,"start":2369,"enrollment":25,"conditions":3193,"interventions":3196},"NCT00660530","Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients",[88],"2009-11",[3194,3195],"Hyperphosphatemia","Kidney Disease",[3180,3197],"Lanthanum carbonate crushed powder",{"trials":3199,"activeCount":99},[],{"trials":3201,"activeCount":99},[],{"trials":3203,"activeCount":99},[],{"intervention":3197,"totalTrials":95,"cells":3205},{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3216,"PHASE4":3218,"NA":3220},{"trials":3207,"activeCount":99},[],{"trials":3209,"activeCount":99},[],{"trials":3211,"activeCount":99},[3212],{"nctId":3189,"briefTitle":3190,"status":478,"phases":3213,"primaryCompletion":3192,"completion":3192,"start":2369,"enrollment":25,"conditions":3214,"interventions":3215},[88],[3194,3195],[3180,3197],{"trials":3217,"activeCount":99},[],{"trials":3219,"activeCount":99},[],{"trials":3221,"activeCount":99},[],{"intervention":2492,"totalTrials":95,"cells":3223},{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3234,"PHASE4":3236,"NA":3238},{"trials":3225,"activeCount":99},[],{"trials":3227,"activeCount":99},[],{"trials":3229,"activeCount":99},[3230],{"nctId":2485,"briefTitle":2486,"status":329,"phases":3231,"primaryCompletion":2488,"completion":2488,"start":1597,"enrollment":2489,"conditions":3232,"interventions":3233},[87,88],[2481],[2492,2465],{"trials":3235,"activeCount":99},[],{"trials":3237,"activeCount":99},[],{"trials":3239,"activeCount":99},[],{"intervention":3241,"totalTrials":435,"cells":3242},"Melphalan",{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3266,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3244,"activeCount":99},[],{"trials":3246,"activeCount":99},[3247,3258],{"nctId":3248,"briefTitle":3249,"status":478,"phases":3250,"primaryCompletion":3251,"completion":3251,"start":3252,"enrollment":565,"conditions":3253,"interventions":3256},"NCT02043847","TMI With HD Mel in ASCT for R\u002FR Multiple Myeloma (BMT-03)",[87],"2016-09-14","2014-01-14",[3254,3255],"Multiple Myeloma, Relapsed","Multiple Myeloma, Refractory to Standard Treatment",[3241,3257,3241,3257,3241,3257],"Filgrastim",{"nctId":3259,"briefTitle":3260,"status":329,"phases":3261,"primaryCompletion":3262,"completion":3262,"start":3263,"enrollment":333,"conditions":3264,"interventions":3265},"NCT02043860","Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma",[87],"2016-11-07","2014-01-10",[623],[3241,3257],{"trials":3267,"activeCount":99},[],{"trials":3269,"activeCount":99},[],{"trials":3271,"activeCount":99},[],{"trials":3273,"activeCount":99},[],{"intervention":1430,"totalTrials":95,"cells":3275},{"EARLY_PHASE1":3276,"PHASE1":3278,"PHASE2":3284,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3277,"activeCount":99},[],{"trials":3279,"activeCount":99},[3280],{"nctId":1423,"briefTitle":1424,"status":329,"phases":3281,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":333,"conditions":3282,"interventions":3283},[87],[1385],[1430,1431,452],{"trials":3285,"activeCount":99},[],{"trials":3287,"activeCount":99},[],{"trials":3289,"activeCount":99},[],{"trials":3291,"activeCount":99},[],{"intervention":1431,"totalTrials":95,"cells":3293},{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3302,"PHASE3":3304,"PHASE4":3306,"NA":3308},{"trials":3295,"activeCount":99},[],{"trials":3297,"activeCount":99},[3298],{"nctId":1423,"briefTitle":1424,"status":329,"phases":3299,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":333,"conditions":3300,"interventions":3301},[87],[1385],[1430,1431,452],{"trials":3303,"activeCount":99},[],{"trials":3305,"activeCount":99},[],{"trials":3307,"activeCount":99},[],{"trials":3309,"activeCount":99},[],{"intervention":3311,"totalTrials":95,"cells":3312},"Alprazolam 2 MG",{"EARLY_PHASE1":3313,"PHASE1":3315,"PHASE2":3331,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3314,"activeCount":99},[],{"trials":3316,"activeCount":99},[3317],{"nctId":3318,"briefTitle":3319,"status":478,"phases":3320,"primaryCompletion":3321,"completion":3322,"start":3323,"enrollment":3324,"conditions":3325,"interventions":3327},"NCT03948243","Licorice Botanical Dietary Supplements - Metabolism and Safety in Women",[87],"2020-07-31","2022-04-22","2019-04-01",19,[3326],"Food-drug Interaction",[3311,3328,3329,3330],"Caffeine 100 MG","Tolbutamide 250 mg","Dextromethorphan 30mg",{"trials":3332,"activeCount":99},[],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[],{"trials":3338,"activeCount":99},[],{"intervention":3328,"totalTrials":95,"cells":3340},{"EARLY_PHASE1":3341,"PHASE1":3343,"PHASE2":3349,"PHASE3":3351,"PHASE4":3353,"NA":3355},{"trials":3342,"activeCount":99},[],{"trials":3344,"activeCount":99},[3345],{"nctId":3318,"briefTitle":3319,"status":478,"phases":3346,"primaryCompletion":3321,"completion":3322,"start":3323,"enrollment":3324,"conditions":3347,"interventions":3348},[87],[3326],[3311,3328,3329,3330],{"trials":3350,"activeCount":99},[],{"trials":3352,"activeCount":99},[],{"trials":3354,"activeCount":99},[],{"trials":3356,"activeCount":99},[],{"intervention":3329,"totalTrials":95,"cells":3358},{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3367,"PHASE3":3369,"PHASE4":3371,"NA":3373},{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[3363],{"nctId":3318,"briefTitle":3319,"status":478,"phases":3364,"primaryCompletion":3321,"completion":3322,"start":3323,"enrollment":3324,"conditions":3365,"interventions":3366},[87],[3326],[3311,3328,3329,3330],{"trials":3368,"activeCount":99},[],{"trials":3370,"activeCount":99},[],{"trials":3372,"activeCount":99},[],{"trials":3374,"activeCount":99},[],{"intervention":3330,"totalTrials":95,"cells":3376},{"EARLY_PHASE1":3377,"PHASE1":3379,"PHASE2":3385,"PHASE3":3387,"PHASE4":3389,"NA":3391},{"trials":3378,"activeCount":99},[],{"trials":3380,"activeCount":99},[3381],{"nctId":3318,"briefTitle":3319,"status":478,"phases":3382,"primaryCompletion":3321,"completion":3322,"start":3323,"enrollment":3324,"conditions":3383,"interventions":3384},[87],[3326],[3311,3328,3329,3330],{"trials":3386,"activeCount":99},[],{"trials":3388,"activeCount":99},[],{"trials":3390,"activeCount":99},[],{"trials":3392,"activeCount":99},[],{"intervention":3394,"totalTrials":95,"cells":3395},"Lanthanum carbonate",{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3410,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3397,"activeCount":99},[],{"trials":3399,"activeCount":99},[3400],{"nctId":3401,"briefTitle":3402,"status":478,"phases":3403,"primaryCompletion":3404,"completion":3405,"start":3406,"enrollment":565,"conditions":3407,"interventions":3409},"NCT00458289","Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate",[87],"2008-06","2008-08","2007-01",[3408],"Hyperphosphatemia in Chronic Kidney Disease",[3394],{"trials":3411,"activeCount":99},[],{"trials":3413,"activeCount":99},[],{"trials":3415,"activeCount":99},[],{"trials":3417,"activeCount":99},[],{"intervention":3419,"totalTrials":95,"cells":3420},"Telavancin",{"EARLY_PHASE1":3421,"PHASE1":3423,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[3425],{"nctId":3426,"briefTitle":3427,"status":478,"phases":3428,"primaryCompletion":3429,"completion":3429,"start":2478,"enrollment":483,"conditions":3430,"interventions":3431},"NCT02753855","Pharmacokinetics of Telavancin in Normal and Obese Subjects",[87],"2016-10",[1353],[3419],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[],{"trials":3437,"activeCount":99},[],{"trials":3439,"activeCount":99},[],{"intervention":295,"totalTrials":95,"cells":3441},{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3450,"PHASE3":3452,"PHASE4":3454,"NA":3456},{"trials":3443,"activeCount":99},[],{"trials":3445,"activeCount":99},[3446],{"nctId":283,"briefTitle":284,"status":285,"phases":3447,"start":287,"enrollment":288,"conditions":3448,"interventions":3449},[87],[29],[291,292,293,294,295],{"trials":3451,"activeCount":99},[],{"trials":3453,"activeCount":99},[],{"trials":3455,"activeCount":99},[],{"trials":3457,"activeCount":99},[],{"intervention":3459,"totalTrials":95,"cells":3460},"Alisertib",{"EARLY_PHASE1":3461,"PHASE1":3463,"PHASE2":3481,"PHASE3":3483,"PHASE4":3485,"NA":3487},{"trials":3462,"activeCount":99},[],{"trials":3464,"activeCount":99},[3465],{"nctId":3466,"briefTitle":3467,"status":478,"phases":3468,"primaryCompletion":3469,"completion":3469,"start":3470,"enrollment":16,"conditions":3471,"interventions":3479},"NCT01639911","Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors",[87],"2016-07-28","2013-08-14",[3472,3473,3474,3475,3476,3477,3478],"Malignant Neoplasm of Breast","CNS Malignancy","Malignant Neoplasm of Gastrointestinal Tract","Genitourinary Neoplasms Malignancy and Gender Unspecified","Head and Neck Neoplasms","Melanoma","Malignant Neoplasm of Thorax",[3459,3480],"Pazopanib",{"trials":3482,"activeCount":99},[],{"trials":3484,"activeCount":99},[],{"trials":3486,"activeCount":99},[],{"trials":3488,"activeCount":99},[],{"intervention":3480,"totalTrials":95,"cells":3490},{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3492,"activeCount":99},[],{"trials":3494,"activeCount":99},[3495],{"nctId":3466,"briefTitle":3467,"status":478,"phases":3496,"primaryCompletion":3469,"completion":3469,"start":3470,"enrollment":16,"conditions":3497,"interventions":3498},[87],[3472,3473,3474,3475,3476,3477,3478],[3459,3480],{"trials":3500,"activeCount":99},[],{"trials":3502,"activeCount":99},[],{"trials":3504,"activeCount":99},[],{"trials":3506,"activeCount":99},[],{"intervention":3508,"totalTrials":95,"cells":3509},"Allogeneic MSC",{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3511,"activeCount":99},[],{"trials":3513,"activeCount":99},[3514],{"nctId":3515,"briefTitle":3516,"status":478,"phases":3517,"primaryCompletion":3518,"completion":3518,"start":3519,"enrollment":3520,"conditions":3521,"interventions":3525},"NCT04626583","Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells",[87],"2023-04-21","2021-03-05",8,[677,3522,3523,3524],"Cornea","Safety","Corneal Defect",[3508],{"trials":3527,"activeCount":99},[],{"trials":3529,"activeCount":99},[],{"trials":3531,"activeCount":99},[],{"trials":3533,"activeCount":99},[],{"intervention":3535,"totalTrials":95,"cells":3536},"Omacetaxine",{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3552,"PHASE3":3554,"PHASE4":3556,"NA":3558},{"trials":3538,"activeCount":99},[],{"trials":3540,"activeCount":99},[3541],{"nctId":3542,"briefTitle":3543,"status":478,"phases":3544,"primaryCompletion":3545,"completion":3546,"start":3547,"enrollment":276,"conditions":3548,"interventions":3550},"NCT04926285","Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)",[87],"2024-01-29","2025-02-06","2022-06-21",[3549],"Relapsed or Refractory Hematologic Malignancies",[3535,3551],"Venetoclax",{"trials":3553,"activeCount":99},[],{"trials":3555,"activeCount":99},[],{"trials":3557,"activeCount":99},[],{"trials":3559,"activeCount":99},[],{"intervention":3551,"totalTrials":95,"cells":3561},{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3570,"PHASE3":3572,"PHASE4":3574,"NA":3576},{"trials":3563,"activeCount":99},[],{"trials":3565,"activeCount":99},[3566],{"nctId":3542,"briefTitle":3543,"status":478,"phases":3567,"primaryCompletion":3545,"completion":3546,"start":3547,"enrollment":276,"conditions":3568,"interventions":3569},[87],[3549],[3535,3551],{"trials":3571,"activeCount":99},[],{"trials":3573,"activeCount":99},[],{"trials":3575,"activeCount":99},[],{"trials":3577,"activeCount":99},[],{"intervention":3579,"totalTrials":95,"cells":3580},"ACTOS",{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3582,"activeCount":99},[],{"trials":3584,"activeCount":99},[3585],{"nctId":3586,"briefTitle":3587,"status":478,"phases":3588,"completion":2078,"start":3589,"enrollment":3590,"conditions":3591,"interventions":3593},"NCT00242177","Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability",[87],"2003-10",30,[3592],"Multiple Sclerosis, Relapsing-Remitting",[3579],{"trials":3595,"activeCount":99},[],{"trials":3597,"activeCount":99},[],{"trials":3599,"activeCount":99},[],{"trials":3601,"activeCount":99},[],{"intervention":3603,"totalTrials":95,"cells":3604},"Selenium, selenomethionine",{"EARLY_PHASE1":3605,"PHASE1":3616,"PHASE2":3618,"PHASE3":3620,"PHASE4":3622,"NA":3624},{"trials":3606,"activeCount":99},[3607],{"nctId":3608,"briefTitle":3609,"status":285,"phases":3610,"primaryCompletion":3611,"completion":3612,"start":2411,"enrollment":158,"conditions":3613,"interventions":3615},"NCT01211561","Colon Cancer Prevention Using Selenium",[86],"2014-12","2016-12",[3614],"Prevention of Colorectal Cancer",[3603],{"trials":3617,"activeCount":99},[],{"trials":3619,"activeCount":99},[],{"trials":3621,"activeCount":99},[],{"trials":3623,"activeCount":99},[],{"trials":3625,"activeCount":99},[],{"intervention":3627,"totalTrials":95,"cells":3628},"MSC Secretome Eye Drops",{"EARLY_PHASE1":3629,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3630,"activeCount":99},[3631],{"nctId":3632,"briefTitle":3633,"status":478,"phases":3634,"primaryCompletion":3635,"completion":3635,"start":3636,"enrollment":3637,"conditions":3638,"interventions":3640},"NCT05204329","Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease",[86],"2024-11-08","2024-01-24",9,[677,3522,3524,3639],"Corneal Epithelium Defect",[3627],{"trials":3642,"activeCount":99},[],{"trials":3644,"activeCount":99},[],{"trials":3646,"activeCount":99},[],{"trials":3648,"activeCount":99},[],{"trials":3650,"activeCount":99},[],{"intervention":3652,"totalTrials":95,"cells":3653},"Longvida curcumin",{"EARLY_PHASE1":3654,"PHASE1":3664,"PHASE2":3666,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3655,"activeCount":99},[3656],{"nctId":3657,"briefTitle":3658,"status":478,"phases":3659,"primaryCompletion":2193,"completion":2193,"start":3660,"enrollment":32,"conditions":3661,"interventions":3663},"NCT04590196","Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients",[86],"2020-11-01",[3662],"Age Related Macular Degeneration",[3652],{"trials":3665,"activeCount":99},[],{"trials":3667,"activeCount":99},[],{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[],{"intervention":3675,"totalTrials":95,"cells":3676},"Verapamil",{"EARLY_PHASE1":3677,"PHASE1":3691,"PHASE2":3693,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3678,"activeCount":99},[3679],{"nctId":3680,"briefTitle":3681,"status":478,"phases":3682,"primaryCompletion":3683,"completion":3683,"start":3684,"enrollment":2514,"conditions":3685,"interventions":3689},"NCT05625503","Dilution of Verapamil During Intraarterial Administration",[86],"2023-12-01","2022-12-13",[3686,3687,3688],"Vasospasm;Peripheral","Burning","Pain",[3675,3690],"Nicardipine",{"trials":3692,"activeCount":99},[],{"trials":3694,"activeCount":99},[],{"trials":3696,"activeCount":99},[],{"trials":3698,"activeCount":99},[],{"trials":3700,"activeCount":99},[],{"intervention":3690,"totalTrials":95,"cells":3702},{"EARLY_PHASE1":3703,"PHASE1":3709,"PHASE2":3711,"PHASE3":3713,"PHASE4":3715,"NA":3717},{"trials":3704,"activeCount":99},[3705],{"nctId":3680,"briefTitle":3681,"status":478,"phases":3706,"primaryCompletion":3683,"completion":3683,"start":3684,"enrollment":2514,"conditions":3707,"interventions":3708},[86],[3686,3687,3688],[3675,3690],{"trials":3710,"activeCount":99},[],{"trials":3712,"activeCount":99},[],{"trials":3714,"activeCount":99},[],{"trials":3716,"activeCount":99},[],{"trials":3718,"activeCount":99},[],{"intervention":3257,"totalTrials":356,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3722,"activeCount":99},[],{"trials":3724,"activeCount":99},[3725,3729,3733],{"nctId":3248,"briefTitle":3249,"status":478,"phases":3726,"primaryCompletion":3251,"completion":3251,"start":3252,"enrollment":565,"conditions":3727,"interventions":3728},[87],[3254,3255],[3241,3257,3241,3257,3241,3257],{"nctId":283,"briefTitle":284,"status":285,"phases":3730,"start":287,"enrollment":288,"conditions":3731,"interventions":3732},[87],[29],[291,292,293,294,295],{"nctId":3259,"briefTitle":3260,"status":329,"phases":3734,"primaryCompletion":3262,"completion":3262,"start":3263,"enrollment":333,"conditions":3735,"interventions":3736},[87],[623],[3241,3257],{"trials":3738,"activeCount":99},[],{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[],{"trials":3744,"activeCount":99},[3745],{"nctId":3746,"briefTitle":3747,"status":478,"phases":3748,"primaryCompletion":3749,"completion":3750,"start":1582,"enrollment":3637,"conditions":3751,"interventions":3753},"NCT02802852","Proteomics and Stem Cell Therapy as a New Vascularization Strategy",[91],"2018-03","2019-03",[3752],"Critical Limb Ischemia",[3257],{"intervention":3755,"totalTrials":95,"cells":3756},"Progestin",{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3758,"activeCount":99},[],{"trials":3760,"activeCount":99},[],{"trials":3762,"activeCount":99},[],{"trials":3764,"activeCount":99},[],{"trials":3766,"activeCount":99},[],{"trials":3768,"activeCount":99},[3769],{"nctId":3770,"briefTitle":3771,"status":329,"phases":3772,"primaryCompletion":1582,"completion":1582,"start":2000,"enrollment":715,"conditions":3773,"interventions":3775},"NCT01718444","Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)",[91],[3096,3774],"Infertility",[3755,3776],"Clomiphene Citrate",{"intervention":3776,"totalTrials":95,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3780,"activeCount":99},[],{"trials":3782,"activeCount":99},[],{"trials":3784,"activeCount":99},[],{"trials":3786,"activeCount":99},[],{"trials":3788,"activeCount":99},[],{"trials":3790,"activeCount":99},[3791],{"nctId":3770,"briefTitle":3771,"status":329,"phases":3792,"primaryCompletion":1582,"completion":1582,"start":2000,"enrollment":715,"conditions":3793,"interventions":3794},[91],[3096,3774],[3755,3776],{"intervention":3796,"totalTrials":95,"cells":3797},"Simvastatin 40 mg",{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3804,"PHASE4":3806,"NA":3808},{"trials":3799,"activeCount":99},[],{"trials":3801,"activeCount":99},[],{"trials":3803,"activeCount":99},[],{"trials":3805,"activeCount":99},[],{"trials":3807,"activeCount":99},[],{"trials":3809,"activeCount":99},[3810],{"nctId":3811,"briefTitle":3812,"status":329,"phases":3813,"primaryCompletion":3814,"completion":3815,"start":3816,"enrollment":351,"conditions":3817,"interventions":3820},"NCT00487461","Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage",[91],"2009-02","2009-06","2007-05",[3818,3819],"Aneurysmal Subarachnoid Hemorrhage","Cerebral Vasospasm",[3796,3821],"Simvastatin 80 mg",{"intervention":3821,"totalTrials":95,"cells":3823},{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3828,"PHASE3":3830,"PHASE4":3832,"NA":3834},{"trials":3825,"activeCount":99},[],{"trials":3827,"activeCount":99},[],{"trials":3829,"activeCount":99},[],{"trials":3831,"activeCount":99},[],{"trials":3833,"activeCount":99},[],{"trials":3835,"activeCount":99},[3836],{"nctId":3811,"briefTitle":3812,"status":329,"phases":3837,"primaryCompletion":3814,"completion":3815,"start":3816,"enrollment":351,"conditions":3838,"interventions":3839},[91],[3818,3819],[3796,3821],{"intervention":3841,"totalTrials":95,"cells":3842},"Regadenoson",{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3849,"PHASE4":3851,"NA":3853},{"trials":3844,"activeCount":99},[],{"trials":3846,"activeCount":99},[],{"trials":3848,"activeCount":99},[],{"trials":3850,"activeCount":99},[],{"trials":3852,"activeCount":99},[],{"trials":3854,"activeCount":99},[3855],{"nctId":3856,"briefTitle":3857,"status":478,"phases":3858,"primaryCompletion":3859,"completion":2292,"start":3860,"enrollment":3861,"conditions":3862,"interventions":3864},"NCT02697877","Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements",[],"2018-02","2016-02",183,[3863],"Coronary Artery Disease",[3841],{"intervention":3866,"totalTrials":95,"cells":3867},"Levothyroxine",{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3869,"activeCount":99},[],{"trials":3871,"activeCount":99},[],{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[],{"trials":3877,"activeCount":99},[],{"trials":3879,"activeCount":99},[3880],{"nctId":3881,"briefTitle":3882,"status":478,"phases":3883,"primaryCompletion":3884,"completion":3884,"start":3885,"enrollment":2319,"conditions":3886,"interventions":3888},"NCT04098991","Improving White Matter Integrity With Thyroid Hormone",[],"2019-11-08","2017-11-08",[3887],"Hypothyroidism",[3866],{"intervention":630,"totalTrials":95,"cells":3890},{"EARLY_PHASE1":3891,"PHASE1":3893,"PHASE2":3895,"PHASE3":3897,"PHASE4":3899,"NA":3901},{"trials":3892,"activeCount":99},[],{"trials":3894,"activeCount":99},[],{"trials":3896,"activeCount":99},[],{"trials":3898,"activeCount":99},[],{"trials":3900,"activeCount":99},[],{"trials":3902,"activeCount":99},[3903],{"nctId":612,"briefTitle":613,"status":478,"phases":3904,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":3905,"interventions":3906},[91],[375,619,620,621,622,623,624,625,626,627,628],[630,631,84],{"intervention":631,"totalTrials":95,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3910,"activeCount":99},[],{"trials":3912,"activeCount":99},[],{"trials":3914,"activeCount":99},[],{"trials":3916,"activeCount":99},[],{"trials":3918,"activeCount":99},[],{"trials":3920,"activeCount":99},[3921],{"nctId":612,"briefTitle":613,"status":478,"phases":3922,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":3923,"interventions":3924},[91],[375,619,620,621,622,623,624,625,626,627,628],[630,631,84],{"intervention":3926,"totalTrials":95,"cells":3927},"Elbasvir\u002FGrazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]",{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3932,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3929,"activeCount":99},[],{"trials":3931,"activeCount":99},[],{"trials":3933,"activeCount":99},[],{"trials":3935,"activeCount":99},[],{"trials":3937,"activeCount":99},[],{"trials":3939,"activeCount":99},[3940],{"nctId":3941,"briefTitle":3942,"status":478,"phases":3943,"primaryCompletion":3944,"completion":3945,"start":3946,"enrollment":351,"conditions":3947,"interventions":3952},"NCT04048850","Zepatier in Patients with Substance Use",[],"2022-06-01","2022-09-09","2019-09-20",[3948,3949,3950,3951],"Hepatitis C","Hiv","Coinfection, HIV","Substance Use Disorders",[3926],{"intervention":3954,"totalTrials":95,"cells":3955},"Levalbuterol",{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3957,"activeCount":99},[],{"trials":3959,"activeCount":99},[],{"trials":3961,"activeCount":99},[],{"trials":3963,"activeCount":99},[],{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[3968],{"nctId":3969,"briefTitle":3970,"status":478,"phases":3971,"primaryCompletion":3972,"completion":3972,"start":3973,"enrollment":3974,"conditions":3975,"interventions":3977},"NCT01833026","COPD Assessment and Management Bundle Versus Usual Care",[91],"2016-05","2013-03",56,[3976],"Chronic Obstructive Pulmonary Disease",[3954],{"intervention":3979,"totalTrials":95,"cells":3980},"Tacrolimus XR",{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3987,"PHASE4":3989,"NA":3991},{"trials":3982,"activeCount":99},[],{"trials":3984,"activeCount":99},[],{"trials":3986,"activeCount":99},[],{"trials":3988,"activeCount":99},[],{"trials":3990,"activeCount":99},[],{"trials":3992,"activeCount":99},[3993],{"nctId":3994,"briefTitle":3995,"status":478,"phases":3996,"primaryCompletion":3997,"completion":3997,"start":2267,"enrollment":889,"conditions":3998,"interventions":4000},"NCT03263052","Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL",[],"2020-01-01",[3999],"Disorder Related to Renal Transplantation",[3979],{"intervention":4002,"totalTrials":95,"cells":4003},"Nicardipine and Nipride",{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4010,"PHASE4":4012,"NA":4014},{"trials":4005,"activeCount":99},[],{"trials":4007,"activeCount":99},[],{"trials":4009,"activeCount":99},[],{"trials":4011,"activeCount":99},[],{"trials":4013,"activeCount":99},[],{"trials":4015,"activeCount":99},[4016],{"nctId":4017,"briefTitle":4018,"status":478,"phases":4019,"completion":4020,"start":4021,"enrollment":4022,"conditions":4023,"interventions":4025},"NCT00490464","Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH",[],"2007-02","2004-06",163,[4024,267],"Subarachnoid Hemorrhage",[4002],{"intervention":4027,"totalTrials":95,"cells":4028},"Clomiphene",{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4033,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4030,"activeCount":99},[],{"trials":4032,"activeCount":99},[],{"trials":4034,"activeCount":99},[],{"trials":4036,"activeCount":99},[],{"trials":4038,"activeCount":99},[],{"trials":4040,"activeCount":99},[4041],{"nctId":4042,"briefTitle":4043,"status":1538,"phases":4044,"primaryCompletion":4045,"completion":4045,"start":2001,"enrollment":99,"conditions":4046,"interventions":4049},"NCT02137265","Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism",[91],"2020-10",[4047,4048],"Non Obstructive Azoospermia","Hypogonadism",[4027],{"intervention":4051,"totalTrials":95,"cells":4052},"Vitamin D 2mg daily for 2 weeks oral paricalcitol",{"EARLY_PHASE1":4053,"PHASE1":4055,"PHASE2":4057,"PHASE3":4059,"PHASE4":4061,"NA":4063},{"trials":4054,"activeCount":99},[],{"trials":4056,"activeCount":99},[],{"trials":4058,"activeCount":99},[],{"trials":4060,"activeCount":99},[],{"trials":4062,"activeCount":99},[],{"trials":4064,"activeCount":99},[4065],{"nctId":4066,"briefTitle":4067,"status":478,"phases":4068,"primaryCompletion":4069,"completion":4069,"start":1561,"enrollment":3520,"conditions":4070,"interventions":4072},"NCT02018133","Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3\u002F4 CKD Patients",[],"2012-06",[4071],"CKD Stage 3\u002F4",[4051],{"intervention":4074,"totalTrials":95,"cells":4075},"Dutasteride",{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4082,"PHASE4":4084,"NA":4086},{"trials":4077,"activeCount":99},[],{"trials":4079,"activeCount":99},[],{"trials":4081,"activeCount":99},[],{"trials":4083,"activeCount":99},[],{"trials":4085,"activeCount":99},[],{"trials":4087,"activeCount":99},[4088],{"nctId":4089,"briefTitle":4090,"status":478,"phases":4091,"primaryCompletion":1727,"completion":4092,"start":4093,"enrollment":4094,"conditions":4095,"interventions":4096},"NCT01594502","Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies",[],"2016-07","2011-09",139,[31],[4074],{"intervention":4098,"totalTrials":95,"cells":4099},"Pentamidine",{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4104,"PHASE3":4106,"PHASE4":4108,"NA":4110},{"trials":4101,"activeCount":99},[],{"trials":4103,"activeCount":99},[],{"trials":4105,"activeCount":99},[],{"trials":4107,"activeCount":99},[],{"trials":4109,"activeCount":99},[],{"trials":4111,"activeCount":99},[4112],{"nctId":4113,"briefTitle":4114,"status":478,"phases":4115,"primaryCompletion":3972,"completion":1582,"start":2000,"enrollment":158,"conditions":4116,"interventions":4118},"NCT02669706","Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia",[],[4117],"Hematologic Malignancy",[4098],{"intervention":4120,"totalTrials":95,"cells":4121},"Antipsychotic",{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4126,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4123,"activeCount":99},[],{"trials":4125,"activeCount":99},[],{"trials":4127,"activeCount":99},[],{"trials":4129,"activeCount":99},[],{"trials":4131,"activeCount":99},[],{"trials":4133,"activeCount":99},[4134],{"nctId":4135,"briefTitle":4136,"status":329,"phases":4137,"primaryCompletion":4138,"completion":4138,"start":3815,"enrollment":565,"conditions":4139,"interventions":4140},"NCT00931996","Oculomotor and Spatial Cognition Deficits in Schizophrenia",[91],"2011-11",[2321],[4120],{"intervention":4142,"totalTrials":95,"cells":4143},"Bezlotoxumab",{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4154},{"trials":4145,"activeCount":99},[],{"trials":4147,"activeCount":99},[],{"trials":4149,"activeCount":99},[],{"trials":4151,"activeCount":99},[],{"trials":4153,"activeCount":99},[],{"trials":4155,"activeCount":99},[4156],{"nctId":4157,"briefTitle":4158,"status":478,"phases":4159,"primaryCompletion":4160,"completion":4160,"start":4161,"enrollment":4162,"conditions":4163,"interventions":4166},"NCT04317963","Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection",[],"2023-02-22","2020-02-12",180,[4164,4165],"Clostridium Difficile Infection","Clostridium Difficile Infection Recurrence",[4142,4167],"Standard CDI treatment",{"intervention":4167,"totalTrials":95,"cells":4169},{"EARLY_PHASE1":4170,"PHASE1":4172,"PHASE2":4174,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4171,"activeCount":99},[],{"trials":4173,"activeCount":99},[],{"trials":4175,"activeCount":99},[],{"trials":4177,"activeCount":99},[],{"trials":4179,"activeCount":99},[],{"trials":4181,"activeCount":99},[4182],{"nctId":4157,"briefTitle":4158,"status":478,"phases":4183,"primaryCompletion":4160,"completion":4160,"start":4161,"enrollment":4162,"conditions":4184,"interventions":4185},[],[4164,4165],[4142,4167]]